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Abstract 
6-Nitro-2,3-dihydroimidazo[2,1-b][1,3]oxazole derivatives were initially studied for 
tuberculosis within a backup program for the clinical trial agent pretomanid (PA-824). 
Phenotypic screening of representative examples against kinetoplastid diseases unexpectedly 
led to the identification of DNDI-VL-2098 as a potential first-in-class drug candidate for 
visceral leishmaniasis (VL). Additional work was then conducted to delineate its essential 
structural features, aiming to improve solubility and safety without compromising activity 
against VL. While the 4-nitroimidazole portion was specifically required, several 
modifications to the aryloxy side chain were well tolerated e.g., exchange of the linking 
oxygen for nitrogen (or piperazine), biaryl extension, and replacement of phenyl rings by 
pyridine. Several less lipophilic analogues displayed improved aqueous solubility, 
particularly at low pH, although stability towards liver microsomes was highly variable. 
Upon evaluation in a mouse model of acute Leishmania donovani infection, one 
phenylpyridine derivative (37) stood out, providing efficacy surpassing that of the original 
preclinical lead.  
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INTRODUCTION 
Neglected tropical diseases (NTDs) affect in excess of one billion people, predominantly in 
the most impoverished areas of the world, causing more than half a million deaths each year, 
as well as much physical suffering and social stigma.1,2 Of the 17 major NTDs, the 
kinetoplastid parasite diseases visceral leishmaniasis (VL), Chagas disease, and human 
African trypanosomiasis (HAT) are considered amongst the most challenging, due to their 
high mortality rates and limited treatment options, with little economic incentive for this to 
change.2 VL is caused by Leishmania donovani (L. don) and Leishmania infantum (L. inf), 
transmitted by female sand flies; these parasites first multiply inside host macrophages before 
spreading to and destroying other tissues (e.g., spleen, liver, and bone marrow).3,4 Annual 
incidence of VL is now estimated at 300000, with infection occurring mainly in rural areas of 
East Africa, India, Bangladesh and Brazil. Most of the ~35000 deaths each year pass 
unrecognised, and in East Africa, lethal epidemics take place frequently.5 However, the 
current treatments for VL are unsatisfactory.3,4 Pentavalent antimonials have been the 
standard first-line remedy since the 1940s, but these are cardiotoxic and require painful 
parenteral administration over 1 month; drug resistance has now severely limited their utility 
in India. A less toxic liposomal form of the antifungal agent, amphotericin B (1; see Figure 
1), has proven widely effective but is limited by high cost. The cheaper aminoglycoside 
antibiotic, paromomycin (2), has variable efficacy, both within and between regions. Finally, 
the alkyl phospholipid miltefosine (3), a long-acting anticancer drug repurposed for VL, is 
the sole oral agent; nevertheless, this also suffers from several disadvantages, including cost, 
teratogenicity, and treatment failures. Hence, there remains an urgent need for more effective, 
safe, and affordable oral treatments for VL. In the last decade of tuberculosis (TB) and NTD 
drug discovery, there has been major interest in exploiting potential development shortcuts, 
via the repurposing of approved drugs, rescue of “failed” clinical agents, or repositioning of 
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early or late stage drug candidates.6-8 Indeed, for organizations such as the Global Alliance for 
TB Drug Development (TB Alliance) and the Drugs for Neglected Diseases initiative 
(DNDi), phenotypic screening is still viewed as a highly useful, cost-effective strategy to 
identify “low hanging fruit”.9-11 Recent cooperation between these two organizations in this 
regard actually provided the foundation for this current study.12 
In early collaborative work with TB Alliance (2005-6) we investigated13 several 
nitroheterobicyclic ring analogues of the bioreductive TB agent pretomanid (PA-824, 4), now 
in phase III clinical evaluation.14 However, our efforts in the known15 6-nitroimidazooxazole 
class were curbed following disclosure of the recently approved16 MDR-TB drug delamanid 
(OPC-67683, 5),17,18 turning our focus for a backup toward the efficacious biaryl analogues of 
4.19-21 Both 4 and 5 are activated by an intracellular deazaflavin dependent nitroreductase 
(Ddn) in Mycobacterium tuberculosis (M. tb), resulting in inhibition of cell wall synthesis as 
well as respiratory poisoning (via nitric oxide release).22 This mode of action is distinct from 
the postulated nucleophilic nitro reduction (e.g., by thiolate) of other new nitroaromatic TB 
agents, such as PBTZ169 (6) and nitrobenzamides, to form reactive nitroso intermediates, 
which trigger suicide inhibition of an enzyme (DprE1) involved in cell wall biosynthesis.23,24 
In late 2009, follow-up interest from DNDi in some promising antileishmanial screening 
data for several of our earlier nitroimidazole derivatives (above) then led to our nomination of 
three unoptimised racemic hits, including two from the most potent 6-nitroimidazooxazole 
class (7 and 8), for proof-of-concept in vivo assessment in a mouse model of VL. In parallel, 
taking into account the preliminary SAR findings, a further 72 compounds were screened 
against L. don in a macrophage-based luciferase assay at the Central Drug Research Institute 
(CDRI, India),25 and 10 of these were later tested in the same mouse model. However, the 
outstanding in vivo efficacy of 7 was not surpassed by any of the other candidates, and 
following our synthesis of its enantiomers and ensuing head-to-head assessments of these, the 
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R enantiomer 9 (DNDI-VL-2098)18 was chosen for preclinical evaluation as a potential first-
in-class drug candidate for VL.25,26 In this report, we initially detail results relevant to the 
selection of 9. We then describe the findings of more recent work aimed at discovering 
backups to 9 having an improved physicochemical/ pharmacological profile and better safety, 
providing wider SAR conclusions for the nitroimidazooxazole class against TB and three 
kinetoplastid NTDs, together with a first in vivo appraisal of the best new leads for VL. 
CHEMISTRY 
Several earlier investigators15,27 prepared 6-nitro-2,3-dihydroimidazo[2,1-b][1,3]oxazoles 
(“oxazoles”) by condensing epoxides with the explosive intermediate 2,4-dinitroimidazole. In 
the interests of improving safety, we first sought alternative conditions using 2-bromo-4-
nitroimidazole (75; see Scheme 1A/1B).13 Satisfactory results for both 2-H and 2-methyl 
glycidyl ethers were obtained by neat reaction with 75 in the presence of a suitable base 
(DIPEA, 105-108 °C) and the resulting (uncyclised) alcohol intermediates were readily 
transformed into the desired oxazoles 7 and 10-12 in high yield (85-90%) upon treatment 
with sodium hydride (DMF, 0 °C). Minor quantities (1-3%) of 5-nitroimidazooxazoles were 
also generated in the first step, with two examples (15 and 87) being isolated for comparison. 
The requisite epoxides (74, 78, 82,28 and 86) were acquired via standard methods, starting 
with (4-OCF3) benzylations of glycidol (73) or 2-methylprop-2-en-1-ol (77), or alkylations of 
4-(trifluoromethoxy)phenol with epibromohydrin (81) or 3-chloro-2-methylprop-1-ene (84). 
To synthesise the enantiomers of 12 and 15 (13, 14, 16, and 17), we employed cesium 
fluoride promoted reactions29 between 4-(trifluoromethoxy)phenol and the chiral glycidyl 
nosylates 89 and 93 (Scheme 1C). The ether products (90 and 94) were then alternatively 
coupled with the more accessible 2-chloro-4-nitroimidazole (91), where the use of toluene as 
cosolvent (DIPEA, 80 °C) enabled better isolated yields of the more thermally labile 5-nitro 
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compounds 16 and 17 (15-16%). In the final step, sodium hydride induced cyclisation of the 
intermediate alcohols (92 and 95) was completed by warming to 20 °C, giving both oxazoles 
13 and 14 in high yield (86-87%) and excellent ee (100%). 
Reaction of the known18,30,31 chiral epoxides 96 and 97 with 4-(trifluoromethoxy)phenol or 
4'-fluorobiphenyl-4-ol in the presence of sodium hydride (Scheme 2A) also provided a direct 
route to the enantiomers of early VL leads 7 and 8, as recorded for 9.18 These epoxides were 
conveniently obtained by the reaction of 2-chloro-4-nitroimidazole (91) with (R) or (S)-2-
methylglycidyl 4-nitrobenzenesulfonate (derived from the Sharpless epoxidation of 2-
methylprop-2-en-1-ol, 77),31 although a multistep approach18 based on the 4-nitrobenzoate 
ester derivative of (S)-2-methylglycidol reportedly achieved a slightly better ee for 96 (98.8% 
vs. 95.9%).30 While isolated yields of the final products 9, 18, 44, and 45 were moderate (33-
44%), these important entities were rapidly produced in excellent chiral purities (>98% ee), 
and a superior kilogram scale process synthesis of 9 has recently been developed.32 
For more efficient generation of additional analogues of 7, we then turned to the known33 
racemic epoxide 98 (Scheme 2B). Heating this epoxide with various phenols and sodium 
hydride furnished the oxazole products 19-23 directly, albeit in variable yields (12-45%), 
depending on the conditions. Alternatively, reaction of 98 with 4-(trifluoromethoxy)aniline 
(or its N-methyl derivative) in the presence of anhydrous cobaltous chloride34 gave 
uncyclised β-anilino alcohols (99 and 100), which could be transformed into the novel 
oxazoles 24 and 25 by careful treatment with sodium hydride (1.3-1.4 equiv). 
Next, in order to access larger quantities of the known30 alcohol 26 for the preparation of 
heteroaryl ethers, we devised an improved plan, comprising TIPS monoprotection of known30 
diol 102, ring closure, and desilylation under acidic conditions (Scheme 2C). Diol 102 was 
obtained from 2-chloro-4-nitroimidazole (91) in two steps (85%), via dihydroxylation of the 
new alkene 101, and elaborated to the oxazole 104 as planned (92% from 102; two steps). 
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However, attempted removal of the TIPS group using a reported acidic method (1% HCl in 
95% EtOH)35 required prolonged heating at 45 °C (4.5 days) and was not clean, leading to a 
suboptimal yield of alcohol 26 (53%). Fortunately, treatment of 104 with hydrofluoric acid in 
acetonitrile36 gave a much better result (95% yield), and 26 was easily converted into various 
heteroaryl ether targets (27, 29-31) via sodium hydride-catalysed SNAr reactions on the 
haloheterocycles 105-108.37 The isomeric pyridine 28 was also obtained in moderate yield 
(25%) by reaction of 6-(trifluoromethyl)pyridin-3-ol and sodium hydride with the known30 
epoxide 109 (Scheme 2D). By way of comparison, epoxides 98 and 109 each afforded 
comparable yields (55% and 51%) for scale-up of racemic VL lead 7. 
In the 2H oxazole series, the synthesis of biphenyl analogues (32-34) was achieved in a 
straightforward manner (Scheme 3A), starting from epibromohydrin (81), and using 
methodology described above (except that DMF was employed in the final step to improve 
solubility). We then envisaged the assembly of related phenylpyridine side chains via Suzuki 
couplings on bromopyridinyl ether derivatives (e.g., 119 in Scheme 3B). To this end, the 
known27 alcohol 117 was prepared in three steps from TBS-protected glycidol (113), via 
condensation with 91, ring closure of alcohol 115, and acid-catalysed desilylation (Scheme 
3B). Unfortunately, reaction of 117 with 5-bromo-2-fluoropyridine (118) under the optimised 
conditions developed for the 2-methyl congener 144 (Scheme 4B) gave a poor yield of ether 
119 (9%), and attempted Suzuki couplings on this substrate (even with weak bases) resulted 
only in decomposition. In an attempt to obtain at least one or two examples featuring this 
isomer pattern, we next considered reversing the order of these final two steps. Here, the 5-
aryl-2-fluoropyridines 120 and 121 were quantitatively obtained from bromide 118 but the 
final alkylations involving alcohol 117 gave very poor yields (<1%) of the authentic products 
35 and 36, precluding synthesis of the less electron deficient 4-fluorophenyl analogue. 
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To circumvent any similar complications in the preparation of the 3-pyridyl targets (37, 40 
and 41), a modified strategy was adopted (Scheme 3C). Here, 6-bromopyridin-3-ol (122) was 
first protected (as the ethoxymethyl ether, 123) and then Suzuki-coupled with arylboronic 
acids. Following acidic deprotection, the 6-arylpyridin-3-ols (125,38 129, and 133) were 
alkylated with epibromohydrin (81) and the resulting epoxides were then elaborated to the 
final products (37, 40 and 41), as above, in consistently good yields (56-59% over the last 2 
steps). For the enantiomers of 37 (38 and 39), we varied this route by reacting the (NaH-
generated) anion of arylpyridinol 12538 with the chiral glycidyl nosylates 89 and 93 (Scheme 
3D). The resulting ether products (136 and 138) were again coupled with 2-chloro-4-
nitroimidazole (91), using toluene as cosolvent (DIPEA, 80 °C) in order to obtain better 
quantities of the 5-nitro isomers 42 and 43 (10-12% yield). Alcohols 137 and 139 were then 
ring closed to the oxazoles 38 and 39 in excellent yields (87-89%), as above. 
Methods for the preparation of biaryl analogues and some soluble bioisosteres in the 2-
methyl oxazole series are outlined in Scheme 4. Epoxide 141 (sourced directly39 from the 
commercial chloride 140) was converted in two steps to the 4-iodophenoxy precursor 143, 
with Suzuki couplings then delivering the biphenyl analogues 8, 46, and 47 (Scheme 4A). 
The bromopyridinyl ethers 144 and 147 (obtained from alcohol 26, and epoxide 98, 
respectively) also proved to be effective Suzuki substrates for creating phenylpyridine and 
bipyridine derivatives (48-56; Scheme 4B/4C), although for bipyridines 55 and 56 it was best 
to use a weaker base (KHCO3). Furthermore, in the case of bipyridine 54, it was necessary to 
employ a copper(I) additive,40 in order to circumvent facile protodeboronation of the required 
2-pyridylpinacol boronate 145 (Scheme 4B). Arylated cyclic amine targets (57 and 58) were 
readily achieved by reaction of epoxide 109 with the commercial amines (148 and 150), 
followed by (NaH-induced) ring closure of the resulting alcohols (149 and 151; Scheme 4D). 
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Lastly, the O-carbamate 59 was made in high yield (86%) by chloroformylation of alcohol 26 
and one-pot coupling with arylpiperazine 148 (Scheme 4E).41 
To conclude this SAR study, several heterocyclic ring A analogues of 7 were synthesized 
from epoxide 86 (Scheme 5). Thus, similar condensations (DIPEA, 104-105 °C) of 86 with 2-
nitroimidazole (152), 5-bromo-3-nitro-1,2,4-triazole (157), or 3,5-dinitropyrazole (158) each 
provided heterobicyclic products directly, although 152 gave equivalent yields of oxazole 61 
and its barely separable alcohol precursor 153 (Scheme 5A). Treatment of the latter with 
sodium hydride (DMF, 0-20 °C) readily cyclised this to 61, in agreement with a recent 
report.42 In the case of 5-bromo-3-nitro-1,2,4-triazole (157), a separable mixture of nitro- and 
bromo-substituted products (70 and 71) was obtained in a ratio of 3:2 (Scheme 5D), 
consistent with initial alkylation at the 1- or 2-positions of the triazole, followed by 
intramolecular substitution of the adjacent bromine or nitro group by the intermediate 
alcohol.43 Reaction of epoxide 86 with 3,5-dinitropyrazole (158) yielded mainly oxazole 72 
(66%), together with a small amount of alcohol 159 (Scheme 5E). 
Finally, alternative condensation of epoxide 86 with 2,4-dibromoimidazole (154) (DIPEA, 
toluene, 109 °C) produced a resolvable mixture of two uncyclised alcohols (155 and 156, in a 
2.4:1 ratio; Scheme 5B), which were transformed into the isomeric oxazoles 62 and 67 upon 
mild heating of their preformed anions (NaH, DMF, 45-55 °C). Bromide 62 was converted 
into the desired methyl sulfone 66 (regarded as a potential bioisostere of 7) via lithiation and 
quenching with methyl disulfide (to give thioether 65), followed by oxidation (m-CPBA), 
after an attempted copper(I) iodide/L-proline sodium salt-induced coupling of 62 with sodium 
methanesulfinate44 proved unsatisfactory (7% yield of crude 66). Similar lithiation of 62 and 
quenching with DMF also gave the aldehyde 63, which was easily reduced (NaBH4) to 
alcohol 64. Methyl sulfone 66 had earlier been sought via displacement of the nitro group in 
7 by methanethiol, based on previous observations. Here, treatment of 7 with methanethiol 
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and triethylamine (10 equiv in MeOH, 0-10 °C) furnished only one major product, 68, which 
upon oxidation gave sulfone 69 (Scheme 5C). A survey of the literature45-47 had suggested 
that cine- or ipso-substitution was possible; therefore, we studied compounds 7, 61, 62, 65, 
67-69, and a 5-nitro intermediate (114) by 2D NMR experiments (e.g., NOESY, ROESY, 
HSQC, and HMBC). The NOE evidence and 13C NMR chemical shift data unambiguously 
established the assigned structures (see Supporting Information), although an absence of any 
three bond correlations between H-5 and C-3 in the HMBC experiments (when four bond 
correlations between H-6 and C-3 were apparent) was initially misleading. Weakly observed 
or missing long range correlations (due to the wide range of nJCH spin coupling constants, 1 to 
50 Hz)48 constitute a well-known deficiency of the standard HMBC experiment, but recent 
HMBC variants also possess some disadvantages (e.g., reduced signal to noise).49 Thus, it 
was verified that thioether 68 was the product of cine-substitution,47 in a fashion reminiscent 
of the Ddn-catalysed addition of hydride to the unsubstituted imidazole carbon atoms of 4 
and 5, leading to loss of the adjacent nitro group (and production of nitric oxide in M. tb).22,23 
RESULTS AND DISCUSSION 
Tables 1 and 2 present in vitro antiparasitic and antitubercular data for 67 compounds (6 
known) from mainly the nitroimidazooxazole class, prepared in two collaborative projects. 
For the TB studies, compounds were screened in two M. tb (strain H37Rv) growth inhibition 
assays, MABA and LORA, respectively conducted under either aerobic (replicating) or 
hypoxic (non-replicating) conditions, as described.50,51 Given that both 4 and 5 exhibit at least 
two distinct mechanisms of action against TB, depending on the oxygenation environment,22 
the LORA assay was regarded as a useful starting tool to identify analogues that may be more 
efficient at killing persistent subpopulations of M. tb in vivo.51,52 Recorded MIC values (for a 
≥90% growth inhibitory effect) are the mean of at least two independent determinations. 
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From 2010-2012, in collaboration with DNDi, new analogues of lead oxazoles 7 and 8 
were screened against L. don in a macrophage-based luciferase assay25 at CDRI, albeit only 
single determinations of the IC50 values were obtained, limiting reliable SAR interpretation. 
Therefore, a wider set of compounds was later evaluated in at least duplicate in vitro assays 
against three tropical protozoan parasites (L. inf, T. cruzi, and T. brucei) at the University of 
Antwerp (LMPH).53 Here, the L. inf assay employed primary peritoneal mouse macrophages 
as the host cell for the amastigotes, whereas the T. cruzi assay utilised human lung fibroblasts 
(MRC-5 cells); compounds having mean IC50 values below 1 µM were considered to be 
highly active. Cytotoxicity on MRC-5 cells was also measured and almost all of the 67 
compounds tested could be regarded as non-toxic (IC50s >30 µM, most >64 µM), in broad 
agreement with assessments on VERO cells (data not shown).50 
In the design of new analogues of 7 and 8, two strategies were employed to enhance 
aqueous solubility while minimising the risk of major potency loss.20,21 First, we focused on 
reducing lipophilicity (probed using CLogP predictions derived from ACD LogP/LogD 
software, version 12.0; Advanced Chemistry Development Inc., Toronto, Canada) via the 
replacement of benzene rings by pyridine, or closely related heterocycles (viz. pyrimidine, 
pyrazine, and pyridazine). This approach enabled CLogP reductions of up to 2.3 units 
(typically ~1.1 units for a single pyridine substitution, although the predicted data displayed 
some variation between isomers). Second, we evaluated the removal of full aromaticity from 
the side chain by the incorporation of a saturated heterocycle (e.g., piperazine or piperidine) 
in combination with a terminal aromatic ring. Arylated cyclic amines are known bioisosteres 
for biaryl moieties21 and can provide improved solubility via salt formation, as well as by the 
disruption of molecular planarity and symmetry.54 Kinetic aqueous solubility values at pH=7 
were determined for selected active compounds, using dry powder forms, while analogous 
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data at pH=1 were measured for examples containing basic functionalities that could form 
hydrochloride salts (based on calculated pKa estimates derived from similar ACD software). 
1. Initial studies relevant to preclinical candidate selection 
The investigations began in late 2009 with the proof-of-concept in vivo assessment of 
oxazoles 7 and 8 in a mouse model of VL at the London School of Hygiene and Tropical 
Medicine (LSHTM). The selection of these two candidates was based on a combination of 
their promising activities in an L. don-infected macrophage assay conducted at the Swiss 
Tropical Institute (later confirmed at CDRI) and reasonable conjecture for their better 
metabolic stabilities in comparison to other similarly active analogues (e.g., 11). In the event, 
both 7 and 8 provided outstanding efficacy in this L. don model at 50 mg/kg (99.9 to 100% 
reduction of the liver parasite burden, after oral dosing once daily for 5 days) and subsequent 
dose-response experiments (Table 3) established that 7 was the most effective lead (ED50s 
were 3.0 and 4.8 mg/kg for 7 and 8, respectively). This result was consistent with 7 having 
superior mouse microsomal stability (79% vs. 57% parent remaining after 30 min, Table 3), 
better aqueous solubility (16-fold), and a more favourable mouse pharmacokinetic profile 
(lower clearance, greater exposure, and higher oral bioavailability; Table 4 and Supporting 
Information, Figure S1) in comparison to 8. 
The more stringent chronic infection hamster model of VL is considered the gold standard 
in vivo assay due to its similar pathology to human disease.55 Here, 5 and 10 day assessments 
of 7 and 8 at CDRI led to opposing conclusions on which oxazole was better (Supporting 
Information, Table S3); therefore, the enantiomers of both compounds were prepared. In the 
mouse model, the R enantiomer of 7 (9) was greatly superior to the S enantiomer (18) and 
was slightly better than 7 itself (83%, 8%, and 64% inhibition at 3.13 mg/kg, respectively; 
Table 3). This was in good agreement with the microsomal stability results (Table 3) and L. 
inf IC50 data (Table 1) showing a 4.5-fold potency difference between 9 and 18. In contrast, 
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although the R enantiomer of 8 (44) was also better than the S enantiomer (45) in this model, 
it was less active than 8 itself (36% vs. 68% at 6.25 mg/kg; Table 3), indicating reduced oral 
exposure (44 and 45 gave sparing aqueous solubilities of ~0.07 µg/mL). A comparative 
appraisal of 7, 9, and 18 in the CDRI hamster model (Supporting Information, Table S3) 
confirmed the preeminent activity of the R enantiomer (9) over the S form (18) and 7 itself, at 
all dose levels.25 Furthermore, dose-response evaluations of 9 and the TB drug delamanid (5) 
in a similar L. inf infected hamster model at LMPH also corroborated the excellent in vivo 
efficacy of 9 (>99% inhibition in 3 target organs at 25 mg/kg; Table 5), whereas 5 displayed a 
weak effect (22-66% at 50 mg/kg), consistent with its poor in vitro potency (IC50 7.1 µM). In 
view of these findings, the decision was made to proceed with 9 as a lead candidate for VL. 
While the initial in vivo work was in progress, the oxazole analogues in hand (7, 8, 10-12, 
46, and 47) were screened against L. don in the macrophage-based luciferase assay at CDRI.25 
Based on these results (Table 1) and some encouraging microsomal stability data (Table 3), 
two additional compounds were identified as worthy of investigation in the VL mouse model. 
These were the (6-fold) more potent des-methyl analogue of 7 (12: IC50 0.005 µM) and the 4-
trifluoromethoxy analogue of 8 (47: IC50 0.05 µM). However, counterintuitively to our 
previous work,19 47 was markedly inferior to 8 for VL (only 42% inhibition at 25 mg/kg), 
while the more potent lead 12 also displayed slightly lower efficacy than 7 (89% inhibition at 
6.25 mg/kg; Table 3). To confirm the latter result, we examined the enantiomers of 12 (13 
and 14), but surprisingly, while the R form (13) was preferred in vitro (Table 1), both 
stereoisomers had an equivalent effect in vivo (~75% at 6.25 mg/kg; Table 3). 
Examination of the pharmacokinetic properties of selected compounds afforded further 
insight (Table 4), revealing that 12 had a higher rate of clearance than 7, gave a lower 
exposure level, and had a concomitantly reduced oral bioavailability (52% vs. 79%), likely 
due in part to its 4-fold lower aqueous solubility (Table 3). Furthermore, while 47 did show 
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better metabolic stability than 8 (decreased clearance and longer half-life; Table 4), it also 
suffered from poor oral absorption (Cmax 0.29 µg/mL; see Supporting Information, Figure S1), 
resulting in modest oral bioavailability (18% cf. 63% for 8). Again, this was consistent with 
the 11-fold lower aqueous solubility of 47 compared to 8 (Table 3) and suggests the need for 
stronger oral formulations when evaluating such sparingly soluble compounds. Thus, the 
early selection of 9 for advanced development12 was validated by the discovery of inferior in 
vivo results for the few alternative candidates that were assessed at the time. 
Following the demonstration of suitable in vivo efficacy and in vivo pharmacokinetics, drug 
discovery for leishmaniasis typically requires several additional ADME and safety studies.56 
For example, many nitroheterocyclic compounds provide positive results in the Ames test for 
mutagenicity; indeed, the development of an early 6-nitroimidazooxazole lead for TB (CGI-
17341) was halted following such a discovery.15 Extensive investigation by Otsuka 
Pharmaceutical Co. established that the introduction of heteroatoms and larger side chain 
functionality (e.g., 5) overcame this effect18,57 and both 8 and 926 were Ames negative. Other 
safety factors (e.g., hERG, CYP inhibition, potential for drug-drug interactions) were also 
broadly acceptable for 9,26 which additionally satisfied such criteria as high stability, low cost 
of synthesis and suitability for once-per-day oral administration noted in the proposed target 
product profile for a VL drug.58 Oral treatment for VL offers many important advantages, 
including convenience and improved patient compliance; it also enables direct delivery of the 
absorbed drug to the liver, a major parasite population site.26 Therefore, the repositioning of 9 
for VL may represent a significant medical breakthrough for this highly neglected disease. 
2. SAR of nitroimidazooxazoles for VL 
In an attempt to better understand the SAR for VL (with a view to further improving drug-
like features, e.g., solubility and safety), additional oxazoles were prepared and screened, first 
at CDRI, and then at LMPH. The latter testing confirmed (Table 1) that this class had no 
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obvious potential for treating HAT (T. brucei IC50s >1 µM, most >64 µM), nor any clear 
utility for Chagas disease (T. cruzi IC50s mostly 1-3 µM, and no new leads were better than 5 
or 8), so the major focus on VL was justified. Nevertheless, in light of the recently reported 
efficacy of fexinidazole (a 5-nitroimidazole derivative) in a mouse model of VL,59 one 
fundamental question was whether 5- or 6-nitroimidazooxazoles were preferred. However, an 
inspection of the data for 15-17 (5-nitro isomers of 12-14 above) immediately showed that 
the 5-nitro analogues were more than two orders of magnitude less effective against L. inf. 
Having established this, compounds 19-23 initially examined the influence of the phenyl 
ring substituent. Interestingly, while the single determination CDRI data (L. don) appeared to 
indicate a clear advantage for 4-trifluoromethoxy (7), this was not supported by the mean IC50 
results vs. L. inf, which pinpointed only the 4-phenoxy analogue (23) as being significantly 
less active, with the remaining compounds (including 7) falling within a ca. 2-fold potency 
range. Replacement of the side chain linking oxygen atom in 7 by nitrogen (24 and 25) was 
also very well tolerated (L. inf IC50s ≤1.5-fold apart), and, in the case of 24, this allowed a 6-
fold solubility improvement (albeit, this compound seemed to be less stable than 7). In 
contrast, removal of the aryl moiety (alcohol 26; ΔCLogP -3.4 units over 7) led to a 55-fold 
loss in VL activity, suggesting that an aryl-based side chain was necessary (as for TB). 
Therefore, we next investigated a small set of trifluoromethyl-substituted heteroaryl ethers 
(27-31). This design concept was based on some partial success with employing 
trifluoromethylpyridine as a more soluble substitute for trifluoromethoxyphenyl in our 
previous TB studies.20,21,37 Pleasingly, pyridine 27 (L. inf IC50 0.24 µM) was slightly more 
potent than both 7 and the direct phenyl equivalent 22, and was 3-fold more soluble than 7 
(11 µg/mL). However, less lipophilic analogues of 27 (28-31) gave 2- to 6-fold poorer IC50 
values against the parasite, despite in two cases (28, 30) providing superior solubility. 
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The SAR focus then switched to targets with phenylpyridine side chains, which could be 
regarded20 as more soluble mimics of the biphenyl lead 8. For completeness, the relatively 
insoluble 2H biphenyls 32-34 were first evaluated and found to be 2- to 6-fold more active 
than their 2-methyl counterparts (8, 46, and 47), similar to the 2-fold higher L. inf potency of 
12 vs. 7. The 2H phenyl-2-pyridines 35 and 36 had comparable or up to 6-fold reduced 
activities compared to the biphenyls 33 and 34, respectively. Conversely, 2H phenyl-3-
pyridine derivatives 37, 40 and 41 were noteworthy for the exceptional potency of the 4-
fluoro compound 37 (L. inf IC50 0.03 µM), which was 11-fold better than 7 and 25-fold 
superior to the 4-trifluoromethoxy analogue 41. 
Similar SAR trends were revealed in the 2-methyl series where, for phenyl-3-pyridine 
derivatives (51-53), the 4-fluoro compound 51 (L. inf IC50 0.13 µM) was overwhelmingly 
more active than congeners 52 and 53 (by 40- to 85-fold). By contrast, in the less soluble and 
more lipophilic (ΔCLogP +0.6 units) isomeric phenyl-2-pyridine series (48-50), the 4-fluoro 
compound 48 (L. inf IC50 2.9 µM) was no better than biphenyl lead 8 or close analogue 49, 
although the 4-trifluoromethoxy derivative 50 was inferior. It was interesting to observe that 
neither 37 nor 51 showed enhanced potencies against the other parasites (or TB) and that both 
compounds displayed ~5-fold better aqueous solubility than 8 at neutral pH, in harmony with 
their decreased lipophilicities (ΔCLogP -1.1 to -1.5 units). This solubility differential over 8 
was considerably larger at low pH (>2000-fold; Table 3), suggesting further promise. 
Therefore the enantiomers of 37 (38 and 39) were also prepared and assessed, together with 
their 5-nitro isomers (42 and 43). Here, unexpectedly, the S enantiomer 39 was the most 
active (2-fold over 38), while the 5-nitro analogues were 3 orders of magnitude less effective. 
Overall, given the superior in vivo efficacy of 8 compared to 47 and the much higher in 
vitro potencies of 37 and 51, it did appear that a 4-fluoro substituent in the terminal ring was 
preferred for VL. Therefore, in the remaining compounds (54-59) we retained this element 
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and probed further modifications expected to improve solubility. Commencing with the 
bipyridines 54-56, the most synthetically challenging isomer 54 was found to be the best (L. 
inf IC50 0.14 µM), having >20-fold higher potencies than the related phenylpyridine 48 and 
the biphenyl congener 8, and 13- to 16-fold greater aqueous solubility than these compounds 
at neutral pH (in accordance with its reduced lipophilicity, ΔCLogP -1.1 to -1.6 units). 
Importantly, more structurally diverse phenylpiperazine and phenylpiperidine analogues (57 
and 58) also retained excellent activities (L. inf IC50s 0.20 and 0.23 µM). As noted above, 
phenylpiperazine and phenylpiperidine are soluble bioisosteres for biphenyl and these 
moieties are now appearing in many new drug candidates.60,61 Here, 57 and 58 were 
respectively 61-fold and 11-fold more soluble than 8 at neutral pH and formed nicely soluble 
hydrochloride salts at low pH (19-23 mg/mL), in line with their calculated pKa values of 5.9 
and 7.3. Finally, based on previous success with an arylpiperazine carbamate analogue of 4 
for TB,41 carbamate 59 was studied, but the additional carboxy group proved detrimental for 
VL (8.5-fold potency loss). There was also a poor tolerance for longer side chains (60 and 5). 
With these SAR results in hand, the next stage of this work was to assess microsomal 
stability and in vivo efficacy for the best new leads. Six racemic compounds (pyridine 27, 
phenylpyridines 37 and 51, bipyridines 54 and 56, and phenylpiperazine 57) were selected as 
representative of both potency and solubility optimisations for the new side chain classes 
investigated here. Unsurprisingly, these diverse compounds demonstrated a wide range of 
metabolic stabilities (Table 3) following 1 h exposures to human and mouse liver microsomes 
(HLM and MLM). While all compounds showed broadly acceptable stabilities towards HLM 
(~50% or more parent remaining), phenylpyridine 51 and phenylpiperazine 57 displayed low 
stabilities toward MLM (14-21% parent), with the others having moderate MLM stabilities 
(47-69% parent). The most stable compounds were pyridine 27 and bipyridine 56, and a 2-H 
substituent (37) appeared to reduce the rate of MLM metabolism (cf. 2-methyl derivative 51). 
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Nevertheless, upon in vivo evaluation in the mouse model of VL (dosing orally at 25 mg/kg 
for 5 consecutive days), all candidates except the least potent one (bipyridine 56) provided 
essentially total parasite clearance (>99.5%), similar to 7, 8, and 12. At 6.25 mg/kg, the more 
rapidly metabolised phenylpiperazine 57 demonstrated poor efficacy (16% inhibition), 
whereas pyridine 27 (83%) was very similar to the des-methyl phenyl ether 12 (89%), 
bipyridine 54 was highly effective (96%), and phenylpyridines 37 and 51 both achieved a 
100% cure (Figure 2 and Table 3). From further dose reductions on 37, 51, and 54, it was 
subsequently established that the highly potent 2H phenylpyridine 37 was the most active 
lead (98% inhibition at 1.56 mg/kg, cf. <50% for 9, 51, and 54), and a final head-to-head 
assessment of its enantiomers determined that the S form was marginally preferred (ED50s 1.3 
and 1.1 mg/kg for 38 and 39), despite demonstrating inferior MLM stability. 
As discussed, a key objective of this work was to identify backups to 9 having an improved 
physicochemical/pharmacological profile. From our study of nitroimidazooxazoles, we have 
discovered several new racemic analogues (e.g., bipyridine 54, and phenylpyridines 37 and 
51) with very high in vivo efficacies in a mouse model of VL, broadly comparable to 9. 
However, 54 could not be regarded as a good candidate for further development due to its 
high synthetic difficulty, while the low metabolic stability of phenylpyridine 51 toward MLM 
would not bode well for its assessment in the more stringent hamster model (where faster 
rates of metabolism were often observed). Thus, the best new racemic lead identified here 
was the phenylpyridine 37, and the most active enantiomer of 37 was 39. With improved 
aqueous solubility under acidic conditions (a calculated pKa value of 3.73), acceptable 
metabolic stability toward HLM, and excellent in vivo efficacy in the mouse model of VL, 
this compound may warrant further investigation as a potential new antileishmanial agent. 
3. SAR of new heterocyclic analogues for NTDs 
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The mechanism of action of these nitroimidazooxazoles against VL is currently unknown. 
It has recently been disclosed that the parasite L. don does not possess a homologue of the M. 
tb nitroreductase Ddn and that compounds such as 4 are not activated by the same type I 
nitroreductase that operates on fexinidazole.62 In addition to this, L. don reportedly does not 
possess the mycolic acid biosynthetic pathway that is present in M. tb and inhibited by 4 and 
5 under aerobic conditions.59 Therefore, as an extension to the current SAR study, we were 
interested in ascertaining which elements of the nitroheterocyclic ring system of 7 were 
essential for the antiparasitic activities observed (L. inf, T. cruzi) and whether or not any new 
ring A analogues could become useful leads. The des-nitro congener of 7 (61) was inactive 
against VL but unexpectedly retained similar potency to 7 against T. cruzi (IC50 2.1 µM; 
Table 2); therefore, a variety of alternative imidazole ring substituents (e.g., Br, CHO, 
CH2OH, SMe, SO2Me) were evaluated (62-69). As expected, such compounds showed almost 
no utility for VL, but the 5-bromo (67) and 5-methylthio (68) analogues provided enhanced 
antitrypanosomal potencies (T. cruzi IC50s 0.13 and 0.58 µM; 6-substituted congeners were 
notably inferior). It is attractive to speculate that the inactivity of 61-69 against L. inf may 
point to a specific requirement for the 6-nitro group of 7 in the mechanism of action, beyond 
simply electronic or protein binding effects. In this work, we have shown that the 6-nitro 
group of 7 can readily undergo cine-substitution by thiolate. Since it has been established that 
nitric oxide is cidal to Leishmania,63 the known capacity of these compounds to produce nitric 
oxide (via loss of the nitro group as nitrous acid) might still be a factor in their VL activity if 
specific nucleophilic activation (e.g., by an active site cysteine thiolate or hydride)23 could 
occur via some other enzyme system within the parasite. 
The remaining compounds in Table 2 (70-72) investigated replacement of the imidazole 
ring by triazole or pyrazole. The direct analogues of 7 (70 and 72) were both completely 
inactive against L. inf, suggesting that in addition to the 6-nitro group, this imidazole ring is 
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also essential for VL activity (mimicking the structural requirements for TB activity13,64). 
Based on measurements in the oxazine series,13 the nitro reduction potentials of 72 and 7 
should be very similar, but 70 and 72 could not undergo the unique ring reduction chemistry 
and nitric oxide release exhibited by 4. Interestingly, the nitrotriazole 70 was more active 
than 7 against T. cruzi (IC50s 0.59 and 1.8 µM, respectively) whereas the bromotriazole 71 
and nitropyrazole 72 were less active. Thus, while the 4-nitroimidazole ring of 7 appeared to 
be essential for retaining utility against VL, a much greater degree of structural variation was 
tolerated for Chagas disease, suggesting a different mechanism of action. The results from 
this investigation may therefore stimulate interest in developing new agents for Chagas 
disease from these rather novel leads. 
4. SAR of nitroimidazooxazoles for TB 
While the major focus of these efforts was directed towards VL, we also examined the 
utility of the new oxazoles against TB, using the in vitro assays described above (Table 1). 
Generally, it appeared that pyridine, phenylpyridine, bipyridine, phenylpiperazine, 
phenylpiperidine, and phenylpiperazine carbamate were all useful side chains for TB, 
consistent with findings in the nitroimidazooxazine series and fairly scant disclosures from 
Otsuka Pharmaceutical Co.31,57 It was particularly fascinating to observe that, except for 12, 
14, and 39, all of the most active VL leads (including 7, 8, and 9, but also 27, 37, 51, and 54) 
possessed notably high antitubercular potencies in the MABA assay (MICs <0.08 µM, 
comparable to 5), despite exhibiting only modest growth inhibitory effects under low oxygen 
conditions (LORA). A closer examination of monoheterocyclic side chains revealed that the 
2-pyridine 27 (MABA MIC 0.038 µM) was indeed optimal (as for VL), but replacement of 
the oxygen linkage in 7 by nitrogen (24, 25) reduced MABA potency by 5-fold. For the new 
biaryl side chain derivatives, phenylpyridines such as 37, 38, 40, 41, and 48-53, as well as 
bipyridine 54, uniformly displayed the highest aerobic activities (MICs ≤0.05 µM), similar or 
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slightly better than the original biphenyl analogues (8, 46, and 47). However, the elusive 2H 
phenyl-2-pyridines 35 and 36 showed dramatically lower potencies in this assay (MICs of 58 
and 5.3 µM), possibly indicating reduced stability. More soluble bioisosteres containing a 
cyclic amine (57-59) also provided slightly inferior results (MABA MICs 0.13-0.29 µM). 
Because of the early promise of 7 and 8 for VL, it was considered worthwhile to evaluate 
the enantiomers of 7 (9 and 18) and the R enantiomer of 8 (44) alongside pretomanid (4) in a 
mouse model of acute TB infection, dosing orally for 3 weeks (daily for 5 days each 
week).19,50 In this assay, both 9 and 44 (100 mg/kg) showed efficacies similar to rifampicin 
(15 mg/kg), respectively 9.3- and 7.6-fold superior to 4, whereas the S enantiomer of 7 (18) 
was slightly less efficacious than 4 (at 100 mg/kg; Figure 3). Nevertheless, the VL lead 9 was 
reportedly much less active than delamanid (5) in a comparable M. tb infection model.18 
CONCLUSIONS 
This study began with discovery of the extraordinary utility of several antitubercular 
oxazole analogues against the neglected kinetoplastid disease VL. Having first identified 9 as 
a preferred lead for preclinical development, we later investigated its SAR, with the objective 
of improving aqueous solubility and other drug-like features without compromising in vivo 
efficacy. All modifications to the nitroheterocycle (viz. removal of the nitro group or 
switching its position, and replacement of the imidazole ring by pyrazole or triazole) resulted 
in a total loss of activity against VL (but not Chagas disease), whereas many aryl-, 
heteroaryl-, and heterobiaryl-based side chains were well tolerated in vitro. Surprisingly, 
there were several significant similarities in these respects to the SAR for TB, while the 
discovery of facile cine-substitution of the nitro group of 7 by thiolate was intriguing. 
Overall, the most effective strategies to enhance aqueous solubility while maintaining or 
increasing potency were the replacement of phenyl rings by pyridine and the use of 
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arylpiperazine and arylpiperidine as bioisosteres for a biaryl moiety. These strategies enabled 
solubility improvements over 7 of 3- to 14-fold at pH = 7 and up to 6400-fold at pH = 1. 
Assessments of stability toward HLM gave broadly acceptable results, although two 
compounds (phenylpyridine 51 and phenylpiperazine 57) had high MLM metabolism rates. 
Further appraisal of six candidates in the acute infection mouse model of VL revealed three 
racemic compounds (phenylpyridines 37 and 51, and bipyridine 54) that displayed efficacies 
at least as strong as 7. Of these, one compound (37) was notably superior, in line with its 
excellent in vitro profile, and subsequent synthesis and evaluation of its enantiomers has 
pinpointed the S form 39 as being the slightly preferred VL lead for further investigation. 
Findings from this work may also inspire interest in these promising compounds for other 
NTDs. 
EXPERIMENTAL SECTION 
Combustion analyses were performed by the Campbell Microanalytical Laboratory, 
University of Otago, Dunedin, New Zealand. Melting points were determined using an 
Electrothermal IA9100 melting point apparatus, and are as read. NMR spectra were measured 
on a Bruker Avance 400 spectrometer at 400 MHz for 1H and 100 MHz for 13C and are 
referenced to Me4Si or solvent resonances. Chemical shifts and coupling constants are recorded 
in units of ppm and hertz, respectively. High-resolution chemical ionisation (HRCIMS) and fast 
atom bombardment (HRFABMS) mass spectra were determined on a VG-70SE mass 
spectrometer at nominal 5000 resolution. High-resolution electrospray ionisation (HRESIMS) 
mass spectra were determined on a Bruker micrOTOF-Q II mass spectrometer. Low-
resolution atmospheric pressure chemical ionisation (APCI) mass spectra were obtained for 
organic solutions using a ThermoFinnigan Surveyor MSQ mass spectrometer, connected to a 
Gilson autosampler. Optical rotations were measured on a Schmidt + Haensch Polartronic 
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NH8 polarimeter. Column chromatography was performed on silica gel (Merck 230-400 mesh). 
Thin-layer chromatography was carried out on aluminium-backed silica gel plates (Merck 60 
F254), with visualization of components by UV light (254 nm), I2, or KMnO4 staining. Tested 
compounds (including batches screened in vivo) were ≥ 95% pure, as determined by 
combustion analysis (results within 0.4% of theoretical values) and/or by HPLC conducted 
on an Agilent 1100 system, using a 150 mm x 3.2 mm Altima 5 µm reversed phase C18 
column with diode array detection. Finally, chiral purity was assessed by HPLC carried out 
on a Gilson Unipoint system (322-H pump, 156 UV/vis detector), employing a 250 mm x 4.6 
mm CHIRALCEL OD 10 µm analytical column, or 250 mm x 4.6 mm CHIRALPAK IA or 
CHIRALPAK AD-H 5.0 µm analytical columns. 
Compounds of Table 1. The following section details the syntheses of compounds 10-13, 
15, 16, 18, 23, 24, 35, 37, 48, 55, and 57 of Table 1, via representative procedures and key 
intermediates, as described in Schemes 1-4. For the syntheses of all of the other compounds 
in Table 1, please refer to Supporting Information. 
Synthesis of 10 (Scheme 1A): 
Procedure A: 2-({[4-(Trifluoromethoxy)benzyl]oxy}methyl)oxirane (74). A solution of 
glycidol (73) (303 mg, 4.09 mmol) and 4-(trifluoromethoxy)benzyl bromide (0.81 mL, 5.06 
mmol) in anhydrous DMF (6 mL) under N2 at 0 °C was treated with 60% NaH (246 mg, 6.15 
mmol), then quickly degassed and resealed under N2. The resulting mixture was stirred at 20 
°C for 7 h and then cooled (CO2/acetone), quenched with ice/aqueous NaHCO3 (100 mL), 
and extracted with EtOAc (4 x 100 mL). The extracts were washed with brine (100 mL) and 
then evaporated to dryness under reduced pressure (at 30 °C), and the residue was 
chromatographed on silica gel. Elution with 0-5% Et2O/petroleum ether first gave foreruns, 
and then further elution with 5-10% Et2O/petroleum ether gave 74 (625 mg, 62%) as a 
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colourless oil; 1H NMR (CDCl3) δ 7.38 (br d, J = 8.7 Hz, 2 H), 7.20 (br d, J = 8.7 Hz, 2 H), 
4.62 (d, J = 12.0 Hz, 1 H), 4.56 (d, J = 12.0 Hz, 1 H), 3.82 (dd, J = 11.5, 2.8 Hz, 1 H), 3.43 
(dd, J = 11.5, 6.0 Hz, 1 H), 3.24-3.18 (m, 1 H), 2.82 (dd, J = 4.9, 4.2 Hz, 1 H), 2.63 (dd, J = 
5.0, 2.7 Hz, 1 H); HRESIMS calcd for C11H11F3NaO3 m/z [M + Na]+ 271.0552, found 271.0557. 
Procedure B: 1-(2-Bromo-4-nitro-1H-imidazol-1-yl)-3-{[4-
(trifluoromethoxy)benzyl]oxy}propan-2-ol (76). A mixture of epoxide 74 (500 mg, 2.01 
mmol), 2-bromo-4-nitro-1H-imidazole (75) (390 mg, 2.03 mmol), and DIPEA (1.75 mL, 10.0 
mmol) in a sealed vial was stirred at 107 °C for 13 h. The resulting cooled mixture was 
dissolved in CH2Cl2 and added to ice/aqueous NaHCO3 (50 mL), then extracted with CH2Cl2 
(5 x 50 mL). The extracts were evaporated to dryness under reduced pressure and the residue 
was chromatographed on silica gel. Elution with 0-1% EtOAc/CH2Cl2 first gave foreruns, and 
then further elution with 1-2% EtOAc/CH2Cl2 gave 76 (538 mg, 61%) as a cream solid: mp 
(CH2Cl2/pentane) 80-81 °C; 1H NMR (CDCl3) δ 7.95 (s, 1 H), 7.35 (br d, J = 8.7 Hz, 2 H), 
7.23 (br d, J = 7.9 Hz, 2 H), 4.57 (s, 2 H), 4.20 (dd, J = 13.6, 2.9 Hz, 1 H), 4.18-4.10 (m, 1 
H), 4.07 (dd, J = 13.4, 7.1 Hz, 1 H), 3.59 (dd, J = 9.6, 4.2 Hz, 1 H), 3.46 (dd, J = 9.6, 5.3 Hz, 
1 H), 2.61 (d, J = 5.0 Hz, 1 H); HRESIMS calcd for C14H14BrF3N3O5 m/z [M + H]+ 442.0044, 
440.0063, found 442.0044, 440.0061. 
Procedure C: 6-Nitro-2-({[4-(trifluoromethoxy)benzyl]oxy}methyl)-2,3-
dihydroimidazo[2,1-b][1,3]oxazole (10). A solution of alcohol 76 (524 mg, 1.19 mmol) in 
anhydrous DMF (12 mL) under N2 at 0 °C was treated with 60% NaH (74 mg, 1.85 mmol), 
then quickly degassed and resealed under N2. The resulting mixture was stirred at 0 °C for 65 
min and then cooled (CO2/acetone), quenched with ice/aqueous NaHCO3 (20 mL), added to 
brine (100 mL), and extracted with CH2Cl2 (6 x 100 mL). The combined extracts were 
evaporated to dryness under reduced pressure (at 30 °C) and the residue was 
chromatographed on silica gel. Elution with CH2Cl2 first gave foreruns, and then further 
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elution with 0-2% EtOAc/CH2Cl2 gave 10 (383 mg, 90%) as a cream solid: mp 
(CH2Cl2/hexane) 134-135 °C; 1H NMR (CDCl3) δ 7.53 (s, 1 H), 7.29 (br d, J = 8.7 Hz, 2 H), 
7.20 (br d, J = 8.0 Hz, 2 H), 5.46-5.38 (m, 1 H), 4.60 (s, 2 H), 4.32 (dd, J = 10.0, 8.6 Hz, 1 
H), 4.26 (dd, J = 10.0, 6.5 Hz, 1 H), 3.89 (dd, J = 11.3, 3.9 Hz, 1 H), 3.78 (dd, J = 11.3, 3.5 
Hz, 1 H). Anal. (C14H12F3N3O5) C, H, N. 
Synthesis of 11 (Scheme 1A): 
1-{[(2-Methylprop-2-en-1-yl)oxy]methyl}-4-(trifluoromethoxy)benzene (78). A solution 
of 2-methylprop-2-en-1-ol (77) (2.34 mL, 27.8 mmol) in anhydrous DMF (10 mL, then 2 x 2 
mL to rinse) was added dropwise to a stirred suspension of 60% NaH (1.32 g, 33.0 mmol) in 
anhydrous DMF (10 mL) under N2 at 0 °C. After 30 min, 4-(trifluoromethoxy)benzyl 
bromide (5.1 mL, 31.9 mmol) was added, and the mixture was stirred at 20 °C for 21 h. The 
resulting mixture was added to ice/aqueous NaHCO3 (200 mL) and extracted with 25% 
EtOAc/petroleum ether (2 x 200 mL) and 50% EtOAc/petroleum ether (3 x 200 mL). The 
extracts were washed with water (200 mL) and then concentrated under reduced pressure, and 
the remaining oil was chromatographed on silica gel. Elution with petroleum ether first gave 
foreruns, and then further elution with 0-5% CH2Cl2/petroleum ether gave 78 (6.57 g, 96%) 
as a colourless oil, which was used directly in the next step; 1H NMR (CDCl3) δ 7.37 (br d, J 
= 8.7 Hz, 2 H), 7.19 (br d, J = 8.0 Hz, 2 H), 5.00 (m, 1 H), 4.94 (m, 1 H), 4.48 (s, 2 H), 3.94 
(br s, 2 H), 1.77 (s, 3 H). 
Procedure D: 2-Methyl-2-({[4-(trifluoromethoxy)benzyl]oxy}methyl)oxirane (79). 3-
Chloroperoxybenzoic acid (19.5 g of 50%, 56.5 mmol) was added to a mixture of alkene 78 
(6.57 g, 26.7 mmol) and disodium hydrogen phosphate (9.87 g, 69.5 mmol) in CH2Cl2 (250 
mL) at 0 °C. The mixture was stirred at 20 °C for 3 h and then added to an ice-cold aqueous 
solution of sodium sulphite (400 mL of 10%) and extracted with CH2Cl2 (3 x 400 mL). The 
extracts were sequentially washed with ice-cold aqueous sodium sulphite solution (400 mL of 
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10%), aqueous NaHCO3 (400 mL), and brine (300 mL), and then the aqueous solutions were 
back-extracted with CH2Cl2 (200 mL). The combined extracts were concentrated under 
reduced pressure and the remaining oil was chromatographed on silica gel. Elution with 0-
15% CH2Cl2/petroleum ether first gave foreruns, and then further elution with 15% 
CH2Cl2/petroleum ether and CH2Cl2 gave 79 (6.53 g, 93%) as a colourless oil; 1H NMR 
(CDCl3) δ 7.37 (br d, J = 8.7 Hz, 2 H), 7.19 (br d, J = 7.9 Hz, 2 H), 4.59 (d, J = 12.1 Hz, 1 
H), 4.54 (d, J = 12.1 Hz, 1 H), 3.61 (d, J = 11.1 Hz, 1 H), 3.44 (d, J = 11.1 Hz, 1 H), 2.75 (d, 
J = 4.9 Hz, 1 H), 2.64 (d, J = 4.9 Hz, 1 H), 1.40 (s, 3 H); HRCIMS (NH3) calcd for 
C12H17F3NO3 m/z [M + NH3 + H]+ 280.1161, found 280.1144. 
1-(2-Bromo-4-nitro-1H-imidazol-1-yl)-2-methyl-3-{[4-(trifluoromethoxy)benzyl]oxy}-
propan-2-ol (80). Reaction of epoxide 79 with 2-bromo-4-nitro-1H-imidazole (75) (1.1 
equiv) and DIPEA (7.6 equiv), using procedure B at 108 °C for 15 h, followed by 
chromatography of the product on silica gel, eluting with CH2Cl2, gave 80 (94%) as a pale 
yellow oil; 1H NMR (CDCl3) δ 8.00 (s, 1 H), 7.33 (br d, J = 8.6 Hz, 2 H), 7.22 (br d, J = 8.0 
Hz, 2 H), 4.56 (s, 2 H), 4.15 (d, J = 14.8 Hz, 1 H), 4.04 (d, J = 14.5 Hz, 1 H), 3.39 (s, 2 H), 
2.51 (s, 1 H), 1.22 (s, 3 H); HRESIMS calcd for C15H16BrF3N3O5 m/z [M + H]+ 456.0200, 
454.0220, found 456.0197, 454.0221. 
2-Methyl-6-nitro-2-({[4-(trifluoromethoxy)benzyl]oxy}methyl)-2,3-
dihydroimidazo[2,1-b][1,3]oxazole (11). Reaction of alcohol 80 with NaH (1.4 equiv), using 
procedure C for 85 min, followed by chromatography of the product on silica gel, eluting 
with CH2Cl2 (foreruns) and then with 0-1% EtOAc/CH2Cl2, gave 11 (87%) as a pale yellow 
solid: mp (CH2Cl2/hexane) 110-111 °C; 1H NMR (CDCl3) δ 7.50 (s, 1 H), 7.26 (br d, J = 8.4 
Hz, 2 H), 7.19 (br d, J = 8.3 Hz, 2 H), 4.59 (d, J = 12.3 Hz, 1 H), 4.56 (d, J = 12.3 Hz, 1 H), 
4.36 (d, J = 10.0 Hz, 1 H), 3.91 (d, J = 10.0 Hz, 1 H), 3.72 (d, J = 10.7 Hz, 1 H), 3.59 (d, J = 
10.6 Hz, 1 H), 1.65 (s, 3 H). Anal. (C15H14F3N3O5) C, H, N. 
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Synthesis of 12 and 15 (Scheme 1B): 
Procedure E: 2-{[4-(Trifluoromethoxy)phenoxy]methyl}oxirane (82). A mixture of 
epibromohydrin (81) (0.30 mL, 3.51 mmol), 4-(trifluoromethoxy)phenol (0.152 mL, 1.17 
mmol), and powdered K2CO3 (260 mg, 1.88 mmol) in acetone (3 mL) in a sealed vial was 
stirred at 59 °C for 36 h. The resulting cooled mixture was filtered, washing with CH2Cl2, and 
then the filtrate was concentrated under reduced pressure and the remaining oil was 
chromatographed on silica gel. Elution with 0-15% CH2Cl2/pentane first gave foreruns, and 
then further elution with 20-25% CH2Cl2/pentane gave 8228 (260 mg, 95%) as a colourless 
oil; 1H NMR (CDCl3) δ 7.14 (br d, J = 9.0 Hz, 2 H), 6.91 (br d, J = 9.1 Hz, 2 H), 4.23 (dd, J 
= 11.1, 3.1 Hz, 1 H), 3.94 (dd, J = 11.1, 5.7 Hz, 1 H), 3.37-3.31 (m, 1 H), 2.91 (dd, J = 4.8, 
4.2 Hz, 1 H), 2.75 (dd, J = 4.9, 2.6 Hz, 1 H); HRFABMS calcd for C10H9F3O3 m/z (M+) 
234.0504, found 234.0508.  
5-Nitro-2-{[4-(trifluoromethoxy)phenoxy]methyl}-2,3-dihydroimidazo[2,1-
b][1,3]oxazole (15) and 1-(2-bromo-4-nitro-1H-imidazol-1-yl)-3-[4-
(trifluoromethoxy)phenoxy]propan-2-ol (83). Reaction of epoxide 82 with 2-bromo-4-
nitro-1H-imidazole (75) (1.1 equiv) and DIPEA, using procedure B at 105 °C for 6.5 h, 
followed by chromatography of the product on silica gel, eluting with CH2Cl2, first gave a 
mixture of oxazole isomers, which was further purified by chromatography on silica gel. 
Elution with 3:1 and 4:1 CH2Cl2/petroleum ether first gave foreruns, and then further elution 
with 4:1 CH2Cl2/petroleum ether and CH2Cl2 gave 15 (2.5%) as a white solid: mp 
(CH2Cl2/pentane) 120-122 °C; 1H NMR (CDCl3) δ 7.68 (s, 1 H), 7.17 (br d, J = 8.5 Hz, 2 H), 
6.90 (br d, J = 9.1 Hz, 2 H), 5.77-5.69 (m, 1 H), 4.71 (dd, J = 10.7, 8.9 Hz, 1 H), 4.61 (dd, J 
= 10.7, 6.9 Hz, 1 H), 4.41 (dd, J = 10.9, 4.1 Hz, 1 H), 4.31 (dd, J = 10.9, 3.8 Hz, 1 H). Anal. 
(C13H10F3N3O5) C, H, N. 
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Further elution of this second column above with 1% EtOAc/CH2Cl2 gave 12 (2%) as a 
white solid (see below). Further elution of the original column above with 0-1% 
EtOAc/CH2Cl2 gave 83 (70%) as a white solid: mp (MeOH/CH2Cl2/hexane) 139-141 °C; 1H 
NMR [(CD3)2SO] δ 8.52 (s, 1 H), 7.30 (br d, J = 9.1 Hz, 2 H), 7.05 (br d, J = 9.2 Hz, 2 H), 
5.66 (br s, 1 H), 4.28 (dd, J = 13.3, 3.3 Hz, 1 H), 4.25-4.17 (m, 1 H), 4.13 (dd, J = 13.3, 8.0 
Hz, 1 H), 4.01 (d, J = 5.0 Hz, 2 H). Anal. (C13H11BrF3N3O5) C, H, N. 
6-Nitro-2-{[4-(trifluoromethoxy)phenoxy]methyl}-2,3-dihydroimidazo[2,1-
b][1,3]oxazole (12). Reaction of alcohol 83 with NaH, using procedure C for 40 min, 
followed by chromatography of the product on silica gel, eluting with CH2Cl2, gave 12 (85%) 
as a cream solid: mp (MeOH/CH2Cl2/hexane) 170-172 °C; 1H NMR [(CD3)2SO] δ 8.16 (s, 1 
H), 7.31 (br d, J = 9.1 Hz, 2 H), 7.05 (br d, J = 9.2 Hz, 2 H), 5.78-5.70 (m, 1 H), 4.50 (dd, J 
= 10.8, 8.9 Hz, 1 H), 4.46 (dd, J = 11.5, 2.8 Hz, 1 H), 4.39 (dd, J = 11.5, 5.2 Hz, 1 H), 4.22 
(dd, J = 10.8, 6.5 Hz, 1 H); 13C NMR [(CD3)2SO] δ 156.8, 156.1, 145.7, 142.2 (q, JC-F = 1.5 
Hz), 122.6 (2 C), 120.1 (q, JC-F = 255.2 Hz), 116.0 (3 C), 85.3, 68.3, 45.1. Anal. 
(C13H10F3N3O5) C, H, N. 
Synthesis of 13 and 16 (Scheme 1C): 
Procedure F: (2R)-2-{[4-(Trifluoromethoxy)phenoxy]methyl}oxirane (90). 4-
(Trifluoromethoxy)phenol (0.22 mL, 1.70 mmol) was added to a suspension of cesium 
fluoride (0.80 g, 5.27 mmol) in anhydrous DMF (1.4 mL) under N2 and the mixture was 
stirred at 20 °C for 1 h. (2R)-Oxiran-2-ylmethyl 3-nitrobenzenesulfonate (89) (446 mg, 1.72 
mmol) was added and the reaction mixture was briefly degassed and resealed under N2 and 
then stirred at 20 °C for 35 h. The resulting mixture was added to water (50 mL) and 
extracted with 50% Et2O/petroleum ether (3 x 50 mL). The extracts were concentrated under 
reduced pressure (at 25 °C) and the remaining oil was chromatographed on silica gel. Elution 
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with 0-15% CH2Cl2/pentane first gave foreruns, and then further elution with 15% 
CH2Cl2/pentane gave 90 (313 mg, 79%) as a colourless oil; 1H NMR (CDCl3) δ 7.14 (br d, J 
= 9.2 Hz, 2 H), 6.91 (br d, J = 9.2 Hz, 2 H), 4.24 (dd, J = 11.0, 3.0 Hz, 1 H), 3.94 (dd, J = 
11.0, 5.8 Hz, 1 H), 3.39-3.32 (m, 1 H), 2.92 (dd, J = 4.8, 4.2 Hz, 1 H), 2.76 (dd, J = 4.9, 2.7 
Hz, 1 H); [α]25D -4.0 (c 2.00, CHCl3); HRESIMS calcd for C10H9F3NaO3 m/z [M + Na]+ 
257.0396, found 257.0399. 
Procedure G: (2R)-5-Nitro-2-{[4-(trifluoromethoxy)phenoxy]methyl}-2,3-
dihydroimidazo[2,1-b][1,3]oxazole (16) and (2R)-1-(2-chloro-4-nitro-1H-imidazol-1-yl)-
3-[4-(trifluoromethoxy)phenoxy]propan-2-ol (92). A mixture of epoxide 90 (202 mg, 0.863 
mmol), 2-chloro-4-nitro-1H-imidazole (91) (141 mg, 0.956 mmol), and DIPEA (0.170 mL, 
0.976 mmol) in anhydrous toluene (1.0 mL) in a sealed vial was stirred at 80 °C for 24 h. The 
resulting cooled mixture was transferred to a flask (in CH2Cl2) and evaporated to dryness 
under reduced pressure (at 30 °C) and the residue was chromatographed on silica gel. Elution 
with CH2Cl2 first gave foreruns, and then further elution with 0.5% EtOAc/CH2Cl2 gave 16 
(47 mg, 16%) as a white solid: mp (CH2Cl2/pentane) 151-152 °C; 1H NMR [(CD3)2SO] δ 7.87 
(s, 1 H), 7.32 (br d, J = 9.0 Hz, 2 H), 7.07 (br d, J = 9.2 Hz, 2 H), 5.93-5.84 (m, 1 H), 4.68 
(dd, J = 10.1, 9.4 Hz, 1 H), 4.48 (dd, J = 11.6, 2.9 Hz, 1 H), 4.43 (dd, J = 11.6, 5.4 Hz, 1 H), 
4.40 (dd, J = 10.1, 6.8 Hz, 1 H); 13C NMR [(CD3)2SO] δ 160.0, 156.7, 142.2 (q, JC-F = 2.0 
Hz), 134.7, 133.5, 122.6 (2 C), 120.1 (q, JC-F = 255.2 Hz), 116.0 (2 C), 87.5, 68.3, 46.3; [α]24D 
-239.0 (c 1.004, DMF). Anal. (C13H10F3N3O5) C, H, N. 
Further elution of the above column with 0.5-1% EtOAc/CH2Cl2 gave 92 (222 mg, 67%) as 
a white solid: mp (CH2Cl2/pentane) 110-111 °C; 1H NMR (CDCl3) δ 7.96 (s, 1 H), 7.19 (br d, 
J = 9.1 Hz, 2 H), 6.90 (br d, J = 9.1 Hz, 2 H), 4.42-4.30 (m, 2 H), 4.21 (dd, J = 14.6, 7.8 Hz, 
1 H), 4.06 (dd, J = 9.5, 4.7 Hz, 1 H), 3.98 (dd, J = 9.5, 5.5 Hz, 1 H), 2.67 (d, J = 5.6 Hz, 1 
H); [α]27D 19.4 (c 2.010, DMF). Anal. (C13H11ClF3N3O5) C, H, N. 
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(2R)-6-Nitro-2-{[4-(trifluoromethoxy)phenoxy]methyl}-2,3-dihydroimidazo[2,1-
b][1,3]oxazole (13). Reaction of alcohol 92 with NaH, using procedure C at 0 °C for 1 h and 
then at 20 °C for 1 h, followed by chromatography of the product on silica gel, eluting with 
CH2Cl2, gave 13 (87%) as a cream solid: mp (CH2Cl2/iPr2O) 179-180 °C; 1H NMR 
[(CD3)2SO] δ 8.17 (s, 1 H), 7.31 (br d, J = 9.0 Hz, 2 H), 7.05 (br d, J = 9.2 Hz, 2 H), 5.78-
5.70 (m, 1 H), 4.50 (dd, J = 10.8, 9.0 Hz, 1 H), 4.45 (dd, J = 11.5, 2.7 Hz, 1 H), 4.39 (dd, J = 
11.5, 5.2 Hz, 1 H), 4.21 (dd, J = 10.8, 6.5 Hz, 1 H); [α]25D -24.9 (c 1.005, DMF). Anal. 
(C13H10F3N3O5) C, H, N. HPLC purity: 100%. 
Chiral HPLC (using a CHIRALPAK IA analytical column and eluting with 15% 
EtOH/hexane at 1 mL/min) determined that the ee of 13 was 100%. 
Synthesis of 18 (Scheme 2A): 
Procedure H: (2S)-2-Methyl-6-nitro-2-{[4-(trifluoromethoxy)phenoxy]methyl}-2,3-
dihydroimidazo[2,1-b][1,3]oxazole (18). 4-(Trifluoromethoxy)phenol (2.21 g, 12.4 mmol) 
was added slowly to a suspension of 60% NaH (0.542 g, 13.6 mmol) in anhydrous DMF (6 
mL) under N2, and the mixture was stirred at 20 °C for 10 min, and then added via cannula to 
a solution of 2-chloro-1-{[(2S)-2-methyloxiran-2-yl]methyl}-4-nitro-1H-imidazole18 (97) 
(2.46 g, 11.3 mmol) in anhydrous DMF (6 mL) at 0 °C under N2. The resulting mixture was 
stirred at 20 °C for 15 min and at 80 °C for 15 min, then cooled, and quenched with water 
(200 mL). Following salt saturation, the mixture was extracted with EtOAc (2 x 200 mL), the 
extracts were evaporated to dryness under reduced pressure, and the residue was 
chromatographed on silica gel. Elution with 0-2% MeOH/CH2Cl2 gave the crude product, 
which was recrystallized from a mixture of CH2Cl2 and iPr2O, to give 18 (1.35 g, 33%) as a 
pale yellow solid: mp 170-171 °C; 1H NMR (CDCl3) δ 7.56 (s, 1 H), 7.16 (br d, J = 8.7 Hz, 2 
H), 6.85 (br d, J = 9.1 Hz, 2 H), 4.48 (d, J = 10.2 Hz, 1 H), 4.23 (d, J = 10.0 Hz, 1 H), 4.09 
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(d, J = 10.1 Hz, 1 H), 4.05 (d, J = 10.2 Hz, 1 H), 1.79 (s, 3 H); [α]25D -9.0 (c 1.002, CHCl3). 
Anal. (C14H12F3N3O5) C, H, N. HPLC purity: 99.6%. 
Chiral HPLC (using a CHIRALPAK AD-H analytical column and eluting with 15% 
EtOH/hexane at 1 mL/min) determined that the ee of 18 was 98.4%. 
Syntheses of 23 and 24 (Scheme 2B): 
Procedure I: 2-Methyl-6-nitro-2-[(4-phenoxyphenoxy)methyl]-2,3-
dihydroimidazo[2,1-b][1,3]oxazole (23). A solution of 2-bromo-1-[(2-methyloxiran-2-
yl)methyl]-4-nitro-1H-imidazole33 (98) (151 mg, 0.576 mmol) and 4-phenoxyphenol (115 
mg, 0.618 mmol) in anhydrous DMF (2 mL) under N2 at 0 °C was treated with 60% NaH (30 
mg, 0.75 mmol), then quickly degassed and resealed under N2. The mixture was stirred at 20 
°C for 10 min and then at 54 °C for 3 h. The resulting mixture was cooled (CO2/acetone) and 
quenched with ice/aqueous NaHCO3 (5 mL), then added to brine (50 mL) and extracted with 
CH2Cl2 (6 x 50 mL). The combined extracts were evaporated to dryness under reduced 
pressure (at 30 °C) and the residue was chromatographed on silica gel. Elution with 25-33% 
EtOAc/petroleum ether first gave foreruns, and then further elution with 33-67% 
EtOAc/petroleum ether gave the crude product, which was further chromatographed on silica 
gel, eluting with CH2Cl2, to give 23 (96 mg, 45%) as a pale yellow solid: mp 
(CH2Cl2/pentane) 127-129 °C; 1H NMR (CDCl3) δ 7.56 (s, 1 H), 7.31 (br dd, J = 8.6, 7.4 Hz, 
2 H), 7.06 (tt, J = 7.4, 1.1 Hz, 1 H), 6.97 (br d, J = 9.1 Hz, 2 H), 6.94 (br dd, J = 8.7, 1.0 Hz, 
2 H), 6.83 (br d, J = 9.1 Hz, 2 H), 4.51 (d, J = 10.2 Hz, 1 H), 4.22 (d, J = 10.1 Hz, 1 H), 4.08 
(d, J = 10.1 Hz, 1 H), 4.04 (d, J = 10.2 Hz, 1 H), 1.79 (s, 3 H). Anal. (C19H17N3O5) C, H, N. 
Procedure J: 1-(2-Bromo-4-nitro-1H-imidazol-1-yl)-2-methyl-3-{[4-
(trifluoromethoxy)phenyl]amino}propan-2-ol (99). A mixture of epoxide 9833 (100 mg, 
0.382 mmol), 4-(trifluoromethoxy)aniline (70 µL, 0.522 mmol), and anhydrous cobalt(II) 
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chloride (20.4 mg, 0.157 mmol) in anhydrous CH3CN (2.2 mL) under N2 was stirred at 63-65 
°C for 52 h. The resulting cooled mixture was added to water (50 mL) and extracted with 
10% MeOH/CH2Cl2 (3 x 50 mL) and CH2Cl2 (2 x 50 mL). The combined extracts were 
concentrated under reduced pressure and the residue was chromatographed on silica gel. 
Elution with 0-0.5% MeOH/CH2Cl2 first gave foreruns and then further elution with 0.5-1% 
MeOH/CH2Cl2 gave 99 (140 mg, 83%) as a yellow solid: mp (MeOH/CH2Cl2/hexane) 158-
160 °C; 1H NMR [(CD3)2SO] δ 8.34 (s, 1 H), 7.06 (br d, J = 8.3 Hz, 2 H), 6.72 (br d, J = 9.1 
Hz, 2 H), 5.81 (br t, J = 6.2 Hz, 1 H), 5.19 (s, 1 H), 4.13 (d, J = 14.3 Hz, 1 H), 4.09 (d, J = 
14.3 Hz, 1 H), 3.09 (d, J = 6.2 Hz, 2 H), 1.10 (s, 3 H); HRESIMS calcd for C14H14BrF3N4NaO4 
m/z [M + Na]+ 463.0024, 461.0043, found 463.0018, 461.0033. 
N-[(2-Methyl-6-nitro-2,3-dihydroimidazo[2,1-b][1,3]oxazol-2-yl)methyl]-4-
(trifluoromethoxy)aniline (24). Reaction of alcohol 99 with NaH (1.3 equiv), using 
procedure C at 20 °C for 75 min, followed by chromatography of the product on silica gel, 
eluting with CH2Cl2, gave 24 (47%) as a light yellow solid: mp (CH2Cl2/pentane) 120-121 °C; 
1H NMR [(CD3)2SO] δ 8.11 (s, 1 H), 7.05 (br d, J = 8.9 Hz, 2 H), 6.74 (br d, J = 9.1 Hz, 2 H), 
6.19 (br t, J = 6.6 Hz, 1 H), 4.20 (d, J = 10.9 Hz, 1 H), 4.10 (d, J = 10.9 Hz, 1 H), 3.53 (dd, J 
= 15.4, 6.7 Hz, 1 H), 3.49 (dd, J = 15.2, 6.6 Hz, 1 H), 1.62 (s, 3 H); 13C NMR [(CD3)2SO] δ 
155.4, 148.1, 145.6, 138.8, 121.9 (2 C), 120.3 (q, JC-F = 254.0 Hz), 116.1, 112.8 (2 C), 96.6, 
51.3, 49.9, 23.1. Anal. (C14H13F3N4O4) C, H, N. 
Synthesis of 35 (Scheme 3B): 
Procedure K: 2-{[(5-Bromopyridin-2-yl)oxy]methyl}-6-nitro-2,3-dihydroimidazo[2,1-
b][1,3]oxazole (119). A solution of (6-nitro-2,3-dihydroimidazo[2,1-b][1,3]oxazol-2-
yl)methanol27 (117) (382 mg, 2.06 mmol) and 5-bromo-2-fluoropyridine (118) (0.70 mL, 6.80 
mmol) in anhydrous DMF (7.5 mL) under N2 at 0 °C was treated with 60% NaH (128 mg, 
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3.20 mmol), then quickly degassed and resealed under N2. Further 118 (0.70 mL, 6.80 mmol) 
was added and the mixture was stirred at 20 °C for 3 h. The resulting mixture was cooled 
(CO2/acetone), quenched with ice/aqueous NaHCO3 (20 mL), then added to brine (100 mL), 
and extracted with CH2Cl2 (8 x 100 mL). The combined extracts were evaporated to dryness 
under reduced pressure (at 30 °C) and the residue was chromatographed on silica gel. Elution 
with 0-2% EtOAc/CH2Cl2 first gave foreruns, and then further elution with 2% 
EtOAc/CH2Cl2 gave 119 (63 mg, 9%) as a cream solid: mp (MeOH/CH2Cl2/hexane) 191-194 
°C; 1H NMR [(CD3)2SO] δ 8.30 (br d, J = 2.6 Hz, 1 H), 8.17 (s, 1 H), 7.93 (dd, J = 8.8, 2.6 
Hz, 1 H), 6.85 (br d, J = 8.8 Hz, 1 H), 5.79-5.70 (m, 1 H), 4.67 (dd, J = 12.5, 2.8 Hz, 1 H), 
4.60 (dd, J = 12.5, 5.6 Hz, 1 H), 4.48 (dd, J = 10.7, 8.9 Hz, 1 H), 4.21 (dd, J = 10.8, 6.7 Hz, 
1 H); HRESIMS calcd for C11H10BrN4O4 m/z [M + H]+ 342.9860, 340.9880, found 342.9861, 
340.9882. 
Procedure L: 2-Fluoro-5-[4-(trifluoromethyl)phenyl]pyridine (120). A stirred mixture 
of 4-(trifluoromethyl)phenylboronic acid (1.43 g, 7.53 mmol) and Pd(dppf)Cl2 (370 mg, 
0.506 mmol) in toluene (50 mL) and EtOH (25 mL) was degassed for 15 min (vacuum pump) 
and then N2 was added. An aqueous solution of Na2CO3 (12.5 mL of 2 M, 25.0 mmol) was 
added by syringe and the stirred mixture was again degassed for 15 min, and then N2 was 
added, followed by 5-bromo-2-fluoropyridine (118) (0.520 mL, 5.05 mmol). The resulting 
mixture was stirred at 85-88 °C for 3 h, and then cooled, diluted with aqueous NaHCO3 (100 
mL), and extracted with CH2Cl2 (5 x 100 mL). The extracts were concentrated under reduced 
pressure (at 30 °C) and the residue was chromatographed on silica gel. Elution with 0-10% 
CH2Cl2/petroleum ether first gave foreruns, and then further elution with 10-20% 
CH2Cl2/petroleum ether gave 120 (1.22 g, 100%) as a cream solid: mp (CH2Cl2/petroleum 
ether) 55-57 °C; 1H NMR (CDCl3) δ 8.45 (br d, J = 2.6 Hz, 1 H), 8.00 (ddd, J = 8.5, 7.5, 2.6 
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Hz, 1 H), 7.75 (br d, J = 8.2 Hz, 2 H), 7.66 (br d, J = 8.1 Hz, 2 H), 7.06 (dd, J = 8.5, 3.0 Hz, 
1 H); HRESIMS calcd for C12H8F4N m/z [M + H]+ 242.0587, found 242.0585. 
6-Nitro-2-[({5-[4-(trifluoromethyl)phenyl]pyridin-2-yl}oxy)methyl]-2,3-
dihydroimidazo[2,1-b][1,3]oxazole (35). A solution of alcohol 11727 (900 mg, 4.86 mmol) 
and fluoropyridine 120 (1.20 g, 4.98 mmol) in anhydrous DMF (4.5 mL) under N2 was 
treated with 60% NaH (280 mg, 7.00 mmol), then quickly degassed and resealed under N2. 
The resulting mixture was stirred at 20 °C for 220 min and then cooled (CO2/acetone), 
quenched with ice/aqueous NaHCO3 (10 mL), added to brine (100 mL), and then filtered 
through Celite, washing with CH2Cl2 (100 mL). The aqueous portion was further extracted 
with CH2Cl2 (5 x 100 mL) and then the combined organic portions were evaporated to 
dryness under reduced pressure (at 30 °C), and the residue was chromatographed on silica 
gel. Elution with 0-12% CH2Cl2/petroleum ether first gave foreruns, and then further elution 
with 20% CH2Cl2/petroleum ether gave recovered 120 (1.16 g). Elution with 0-0.33% 
MeOH/CH2Cl2 gave foreruns, and then further elution with 0.5% MeOH/CH2Cl2 gave 35 (18 
mg, 0.9%) as a cream solid: mp (MeOH/CH2Cl2/pentane) 165-168 °C (dec.); 1H NMR 
[(CD3)2SO] δ 8.58 (br d, J = 2.6 Hz, 1 H), 8.18 (s, 1 H), 8.14 (dd, J = 8.7, 2.6 Hz, 1 H), 7.91 
(br d, J = 8.2 Hz, 2 H), 7.82 (br d, J = 8.4 Hz, 2 H), 6.98 (br d, J = 8.7 Hz, 1 H), 5.83-5.74 
(m, 1 H), 4.77 (dd, J = 12.5, 2.8 Hz, 1 H), 4.70 (dd, J = 12.5, 5.5 Hz, 1 H), 4.52 (dd, J = 
10.7, 8.9 Hz, 1 H), 4.25 (dd, J = 10.8, 6.7 Hz, 1 H); 13C NMR [(CD3)2SO] δ 162.6, 156.2, 
145.7, 145.1, 140.8, 138.3, 128.5, 127.9 (q, JC-F = 31.9 Hz), 127.1 (2 C), 125.8 (q, JC-F = 3.7 
Hz, 2 C), 124.3 (q, JC-F = 271.8 Hz), 116.0, 111.0, 85.4, 65.7, 45.2; HRESIMS calcd for 
C18H14F3N4O4 m/z [M + H]+ 407.0962, found 407.0961. HPLC purity: 98.8%. 
Synthesis of 37 (Scheme 3C): 
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2-Bromo-5-(ethoxymethoxy)pyridine (123). Chloromethyl ethyl ether (4.00 mL, 43.1 
mmol) was added dropwise to a cooled mixture of 6-bromopyridin-3-ol (122) (5.00 g, 28.7 
mmol) and K2CO3 (7.97 g, 57.7 mmol) in anhydrous DMF (20 mL) under N2 at 0 °C, and then 
the mixture was stirred at 0-20 °C for 24 h. The resulting mixture was added to ice-water 
(180 mL) and extracted with 50% Et2O/petroleum ether (5 x 80 mL). The extracts were 
washed with brine (100 mL) and then concentrated under reduced pressure to give an oil, 
which was chromatographed on silica gel. Elution with 0-2% Et2O/petroleum ether first gave 
foreruns, and then further elution with 2.5-4% Et2O/petroleum ether gave 123 (5.25 g, 79%) 
as a colourless oil; 1H NMR (CDCl3) δ 8.18 (br d, J = 3.0 Hz, 1 H), 7.38 (br d, J = 8.7 Hz, 1 
H), 7.28 (dd, J = 8.7, 3.0 Hz, 1 H), 5.23 (s, 2 H), 3.72 (q, J = 7.1 Hz, 2 H), 1.22 (t, J = 7.1 
Hz, 3 H); HRESIMS calcd for C8H11BrNO2 m/z [M + H]+ 233.9947, 231.9968, found 233.9940, 
231.9962. 
5-(Ethoxymethoxy)-2-(4-fluorophenyl)pyridine (124). Reaction of bromide 123 with 4-
fluorophenylboronic acid (1.8 equiv) and Pd(dppf)Cl2 (0.25 equiv), using procedure L for 4.5 
h, followed by chromatography of the product on silica gel, eluting with 0-2% 
Et2O/petroleum ether (foreruns) and then with 4% Et2O/petroleum ether, gave 124 (97%) as a 
colourless oil; 1H NMR (CDCl3) δ 8.46 (br d, J = 2.9 Hz, 1 H), 7.91 (br dd, J = 9.0, 5.4 Hz, 2 
H), 7.61 (br d, J = 8.7 Hz, 1 H), 7.45 (dd, J = 8.7, 2.9 Hz, 1 H), 7.13 (br t, J = 8.8 Hz, 2 H), 
5.28 (s, 2 H), 3.76 (q, J = 7.1 Hz, 2 H), 1.24 (t, J = 7.1 Hz, 3 H); HRESIMS calcd for 
C14H15FNO2 m/z [M + H]+ 248.1081, found 248.1084. 
Procedure M: 6-(4-Fluorophenyl)pyridin-3-ol (125). Ethoxymethyl ether 124 (719 mg, 
2.91 mmol) was treated with a solution of HCl in MeOH (20 mL of 1.25 M, 25 mmol) and the 
mixture was stirred at 54 °C for 5 h. The resulting cooled solution was added to ice-water (80 
mL) and neutralised with Na2CO3 (to pH=6) to give a cream precipitate, which was filtered, 
washing with water and pentane, to give some product 12538 (361 mg, 66%). The filtrate was 
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saturated with salt and extracted with CH2Cl2 (4 x 100 mL) and EtOAc (3 x 100 mL), then the 
combined extracts were concentrated to dryness under reduced pressure. The residue was 
suspended in CH2Cl2 and filtered to remove salt, and then the filtrate was concentrated to 
dryness under reduced pressure and triturated in petroleum ether to give further 12538 (160 mg, 
29%) as a cream solid: mp 142-144 °C (lit.38 mp 145-147 °C); 1H NMR [(CD3)2SO] δ 10.03 
(s, 1 H), 8.20 (br d, J = 2.9 Hz, 1 H), 8.00 (br dd, J = 9.0, 5.6 Hz, 2 H), 7.78 (br d, J = 8.7 Hz, 
1 H), 7.29-7.21 (m, 3 H); HRESIMS calcd for C11H9FNO m/z [M + H]+ 190.0663, found 
190.0659. 
Procedure N: 2-(4-Fluorophenyl)-5-(oxiran-2-ylmethoxy)pyridine (126). A mixture of 
epibromohydrin (81) (0.24 mL, 2.80 mmol), pyridinol 125 (250 mg, 1.32 mmol), and 
powdered K2CO3 (550 mg, 3.98 mmol) in MEK (5.0 mL) in a sealed vial was stirred at 65 °C 
for 49 h. The resulting cooled mixture was filtered, washing with CH2Cl2, and then the filtrate 
was concentrated under reduced pressure and the residue was chromatographed on silica gel. 
Elution with CH2Cl2 first gave foreruns, and then further elution with 0-2% Et2O/CH2Cl2 gave 
126 (274 mg, 85%) as a white solid: mp (CH2Cl2/pentane) 80-81 °C; 1H NMR (CDCl3) δ 8.39 
(br d, J = 2.9 Hz, 1 H), 7.90 (br dd, J = 8.9, 5.4 Hz, 2 H), 7.62 (br d, J = 8.7 Hz, 1 H), 7.31 
(dd, J = 8.7, 3.0 Hz, 1 H), 7.13 (br t, J = 8.7 Hz, 2 H), 4.36 (dd, J = 11.1, 2.9 Hz, 1 H), 4.03 
(dd, J = 11.1, 5.8 Hz, 1 H), 3.42-3.37 (m, 1 H), 2.95 (dd, J = 4.8, 4.2 Hz, 1 H), 2.80 (dd, J = 
4.9, 2.6 Hz, 1 H); HRESIMS calcd for C14H13FNO2 m/z [M + H]+ 246.0925, found 246.0931. 
1-(2-Chloro-4-nitro-1H-imidazol-1-yl)-3-{[6-(4-fluorophenyl)pyridin-3-yl]oxy}propan-
2-ol (127). Reaction of epoxide 126 with 2-chloro-4-nitro-1H-imidazole (91) (1.1 equiv) and 
DIPEA (10 equiv), using procedure B at 100 °C for 12 h, followed by chromatography of the 
product on silica gel, eluting with 0-1% MeOH/CH2Cl2 (foreruns) and then with 1-1.5% 
MeOH/CH2Cl2, gave 127 (69%) as a pale yellow solid: mp (CH2Cl2/pentane) 181-182 °C; 1H 
NMR [(CD3)2SO] δ 8.54 (s, 1 H), 8.38 (br d, J = 2.7 Hz, 1 H), 8.06 (br dd, J = 9.0, 5.5 Hz, 2 
 37 
H), 7.92 (br d, J = 8.6 Hz, 1 H), 7.50 (dd, J = 8.8, 3.0 Hz, 1 H), 7.28 (br t, J = 8.9 Hz, 2 H), 
5.73 (d, J = 5.2 Hz, 1 H), 4.32 (dd, J = 13.2, 3.0 Hz, 1 H), 4.29-4.20 (m, 1 H), 4.18 (dd, J = 
13.2, 7.9 Hz, 1 H), 4.13 (br d, J = 4.9 Hz, 2 H); HRESIMS calcd for C17H15ClFN4O4 m/z [M + 
H]+ 395.0732, 393.0760, found 395.0739, 393.0762. 
2-({[6-(4-Fluorophenyl)pyridin-3-yl]oxy}methyl)-6-nitro-2,3-dihydroimidazo[2,1-
b][1,3]oxazole (37). Reaction of alcohol 127 with NaH, using procedure C at 0 °C for 1 h and 
then at 20 °C for 40 min, followed by chromatography of the product on silica gel, eluting 
with 0-0.5% MeOH/CH2Cl2 (foreruns) and then with 1% MeOH/CH2Cl2, gave 37 (85%) as a 
cream solid: mp (MeOH/CH2Cl2/hexane) 211-213 °C; 1H NMR [(CD3)2SO] δ 8.37 (br d, J = 
2.7 Hz, 1 H), 8.18 (s, 1 H), 8.06 (br dd, J = 9.0, 5.6 Hz, 2 H), 7.93 (br d, J = 8.6 Hz, 1 H), 
7.52 (dd, J = 8.8, 3.0 Hz, 1 H), 7.28 (br t, J = 8.9 Hz, 2 H), 5.82-5.74 (m, 1 H), 4.58 (dd, J = 
11.7, 2.7 Hz, 1 H), 4.52 (dd, J = 10.7, 8.9 Hz, 1 H), 4.51 (dd, J = 11.7, 5.3 Hz, 1 H), 4.24 
(dd, J = 10.8, 6.6 Hz, 1 H); 13C NMR [(CD3)2SO] δ 162.4 (d, JC-F = 245.2 Hz), 156.1, 153.5, 
148.3, 145.7, 137.5, 134.8 (d, JC-F = 2.7 Hz), 128.1 (d, JC-F = 8.2 Hz, 2 C), 122.6, 120.6, 
116.0, 115.5 (d, JC-F = 21.4 Hz, 2 C), 85.4, 68.3, 45.0. Anal. (C17H13FN4O4) C, H, N. 
Syntheses of 48 and 55 (Scheme 4B): 
2-{[(5-Bromopyridin-2-yl)oxy]methyl}-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-
b][1,3]oxazole (144). Reaction of alcohol 2630 with 5-bromo-2-fluoropyridine (118) and 
NaH, using procedure K for 2.5 h, followed by chromatography of the product on silica gel, 
eluting with 0-1.5% EtOAc/CH2Cl2 (foreruns) and then with 1.5-2% EtOAc/CH2Cl2, gave 
144 (46%) as a cream solid: mp (CH2Cl2/hexane) 151-153 °C; 1H NMR (CDCl3) δ 8.17 (br d, 
J = 2.5 Hz, 1 H), 7.68 (dd, J = 8.8, 2.5 Hz, 1 H), 7.52 (s, 1 H), 6.60 (br d, J = 8.7 Hz, 1 H), 
4.58 (d, J = 12.0 Hz, 1 H), 4.50 (d, J = 12.0 Hz, 1 H), 4.41 (d, J = 10.2 Hz, 1 H), 4.01 (d, J = 
10.2 Hz, 1 H), 1.76 (s, 3 H). Anal. (C12H11BrN4O4) C, H, N. 
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Procedure O: 2-({[5-(4-Fluorophenyl)pyridin-2-yl]oxy}methyl)-2-methyl-6-nitro-2,3-
dihydroimidazo[2,1-b][1,3]oxazole (48). A stirred mixture of bromide 144 (77.2 mg, 0.217 
mmol), 4-fluorophenylboronic acid (58.0 mg, 0.415 mmol) and Pd(dppf)Cl2 (43.5 mg, 0.059 
mmol) in DMF (2.3 mL), toluene (1.6 mL) and EtOH (1.1 mL) was degassed for 9 min 
(vacuum pump) and then N2 was added. An aqueous solution of Na2CO3 (0.55 mL of 2 M, 1.1 
mmol) was added by syringe and the stirred mixture was again degassed for 9 min, and then 
N2 was added. The resulting mixture was stirred at 90 °C for 3 h, and then cooled, diluted 
with aqueous NaHCO3 (50 mL), and extracted with CH2Cl2 (6 x 50 mL). The extracts were 
evaporated to dryness under reduced pressure (at 30 °C) and the residue was 
chromatographed on silica gel. Elution with 0-1% EtOAc/CH2Cl2 first gave foreruns, and 
then further elution with 1-2% EtOAc/CH2Cl2 gave 48 (60 mg, 75%) as a cream solid: mp 
(CH2Cl2/hexane) 162-164 °C; 1H NMR [(CD3)2SO] δ 8.45 (br d, J = 2.6 Hz, 1 H), 8.16 (s, 1 
H), 8.01 (dd, J = 8.6, 2.6 Hz, 1 H), 7.70 (br dd, J = 8.9, 5.4 Hz, 2 H), 7.29 (br t, J = 8.9 Hz, 2 
H), 6.84 (br d, J = 8.6 Hz, 1 H), 4.64 (d, J = 12.1 Hz, 1 H), 4.61 (d, J = 12.1 Hz, 1 H), 4.40 
(d, J = 11.0 Hz, 1 H), 4.21 (d, J = 11.0 Hz, 1 H), 1.71 (s, 3 H); 13C NMR [(CD3)2SO] δ 162.0, 
161.9 (d, JC-F = 244.5 Hz), 155.5, 145.6, 144.4, 138.0, 133.2 (d, JC-F = 3.1 Hz), 129.1, 128.4 
(d, JC-F = 8.2 Hz, 2 C), 116.0, 115.8 (d, JC-F = 21.4 Hz, 2 C), 110.7, 94.2, 69.0, 51.0, 22.0. 
Anal. (C18H15FN4O4) C, H, N. 
Procedure P: 2-{[(6'-Fluoro-[3,3'-bipyridin]-6-yl)oxy]methyl}-2-methyl-6-nitro-2,3-
dihydroimidazo[2,1-b][1,3]oxazole (55). A stirred mixture of bromide 144 (80.3 mg, 0.226 
mmol), (6-fluoropyridin-3-yl)boronic acid (57.4 mg, 0.407 mmol) and Pd(dppf)Cl2 (50.1 mg, 
0.068 mmol) in DMF (2.3 mL), toluene (1.5 mL) and EtOH (1.1 mL) was degassed for 8 min 
(vacuum pump) and then N2 was added. An aqueous solution of KHCO3 (0.55 mL of 2 M, 1.1 
mmol) was added by syringe and the stirred mixture was again degassed for 10 min, and then 
N2 was added. The resulting mixture was stirred at 82 °C for 3 h, and then cooled, diluted 
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with aqueous NaHCO3 (50 mL), and extracted with CH2Cl2 (6 x 50 mL). The extracts were 
evaporated to dryness under reduced pressure (at 30 °C) and the residue was 
chromatographed on silica gel. Elution with 0-0.4% MeOH/CH2Cl2 first gave foreruns, and 
then further elution with 0.4-0.5% MeOH/CH2Cl2 gave 55 (67 mg, 80%) as a pale brown 
solid: mp (CH2Cl2/hexane) 161-163 °C; 1H NMR (CDCl3) δ 8.36 (br d, J = 2.5 Hz, 1 H), 8.29 
(br d, J = 2.5 Hz, 1 H), 7.91 (ddd, J = 8.5, 7.5, 2.6 Hz, 1 H), 7.76 (dd, J = 8.6, 2.6 Hz, 1 H), 
7.55 (s, 1 H), 7.04 (br dd, J = 8.5, 3.0 Hz, 1 H), 6.79 (br d, J = 8.6 Hz, 1 H), 4.70 (d, J = 12.0 
Hz, 1 H), 4.58 (d, J = 12.0 Hz, 1 H), 4.47 (d, J = 10.2 Hz, 1 H), 4.05 (d, J = 10.2 Hz, 1 H), 
1.80 (s, 3 H). Anal. (C17H14FN5O4) C, H, N. 
Synthesis of 57 (Scheme 4D): 
Procedure Q: 1-(2-Chloro-4-nitro-1H-imidazol-1-yl)-3-[4-(4-fluorophenyl)piperazin-1-
yl]-2-methylpropan-2-ol (149). A mixture of 2-chloro-1-[(2-methyloxiran-2-yl)methyl]-4-
nitro-1H-imidazole30 (109) (130 mg, 0.597 mmol) and 1-(4-fluorophenyl)piperazine (148) 
(151 mg, 0.838 mmol) in MEK (2.5 mL) in a sealed vial was stirred at 65 °C for 3 d. The 
resulting cooled mixture was transferred to a flask (in CH2Cl2) and evaporated to dryness 
under reduced pressure (at 30 °C), and then the residue was chromatographed on silica gel. 
Elution with 0-33% EtOAc/petroleum ether first gave foreruns, and then further elution with 
33-40% EtOAc/petroleum ether gave 149 (208 mg, 88%) as a yellow solid: mp 
(CH2Cl2/pentane) 158-160 °C; 1H NMR (CDCl3) δ 8.06 (s, 1 H), 6.97 (br dd, J = 9.2, 8.3 Hz, 
2 H), 6.86 (br dd, J = 9.2, 4.6 Hz, 2 H), 4.02 (s, 2 H), 3.42 (br s, 1 H), 3.12 (t, J = 4.8 Hz, 4 
H), 2.87 (dt, J = 11.2, 4.9 Hz, 2 H), 2.74 (dt, J = 11.4, 4.9 Hz, 2 H), 2.55 (d, J = 13.9 Hz, 1 
H), 2.42 (d, J = 13.9 Hz, 1 H), 1.16 (s, 3 H); HRESIMS calcd for C17H22ClFN5O3 m/z [M + H]+ 
400.1366, 398.1390, found 400.1368, 398.1390. 
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2-{[4-(4-Fluorophenyl)piperazin-1-yl]methyl}-2-methyl-6-nitro-2,3-
dihydroimidazo[2,1-b][1,3]oxazole (57). Reaction of alcohol 149 with NaH, using 
procedure C, followed by chromatography of the product on silica gel, eluting with 50% 
EtOAc/petroleum ether (foreruns) and then with 0-2% MeOH/CH2Cl2 (saturated with NH3), 
gave 57 (75%) as a light yellow solid: mp 160-161 °C; 1H NMR [(CD3)2SO] δ 8.12 (s, 1 H), 
7.00 (br dd, J = 9.1, 8.7 Hz, 2 H), 6.88 (br dd, J = 9.3, 4.7 Hz, 2 H), 4.26 (d, J = 10.7 Hz, 1 
H), 4.07 (d, J = 10.7 Hz, 1 H), 2.96 (dt, J = 11.7, 4.9 Hz, 2 H), 2.88 (dt, J = 11.6, 4.8 Hz, 2 
H), 2.81 (d, J = 14.8 Hz, 1 H), 2.76 (d, J = 14.7 Hz, 1 H), 2.72-2.61 (m, 4 H), 1.56 (s, 3 H); 
13C NMR [(CD3)2SO] δ 155.9 (d, JC-F = 235.4 Hz), 155.5, 147.8, 145.5, 116.9 (d, JC-F = 7.7 
Hz, 2 C), 115.9, 115.2 (d, JC-F = 21.9 Hz, 2 C), 97.2, 63.3, 54.2 (2 C), 51.6, 49.1 (2 C), 23.3. 
Anal. (C17H20FN5O3) C, H, N. 
Compounds of Table 2. The following section details the syntheses of compounds 62 and 
65 of Table 2, as described in Scheme 5. For the syntheses of all of the other compounds in 
Table 2, please refer to Supporting Information. 
Syntheses of 62 and 65 (Scheme 5B): 
1-(2,4-Dibromo-1H-imidazol-1-yl)-2-methyl-3-[4-(trifluoromethoxy)phenoxy]propan-
2-ol (155) and 1-(2,5-dibromo-1H-imidazol-1-yl)-2-methyl-3-[4-(trifluoromethoxy)-
phenoxy]propan-2-ol (156). Reaction of epoxide 86 (see Supporting Information) with 2,4-
dibromo-1H-imidazole (154) (1.05 equiv) and DIPEA in anhydrous toluene, using procedure 
G at 109 °C for 12 h, followed by chromatography of the product on silica gel, eluting with 
CH2Cl2 (foreruns) and then with additional CH2Cl2, first gave the crude major product (155). 
This was further purified by chromatography on silica gel, eluting with CH2Cl2 (to remove a 
minor higher running impurity) and then with 0-1% Et2O/CH2Cl2 (to give the product), and 
by additional chromatography on silica gel, eluting with 0-25% Et2O/petroleum ether 
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(foreruns, including excess 154) and then with CH2Cl2, to give 155 (69%) as a colourless oil; 
1H NMR (CDCl3) δ 7.18 (s, 1 H), 7.17 (br d, J = 8.9 Hz, 2 H), 6.88 (br d, J = 9.2 Hz, 2 H), 
4.16 (d, J = 14.6 Hz, 1 H), 4.08 (d, J = 14.6 Hz, 1 H), 3.86 (d, J = 9.0 Hz, 1 H), 3.81 (d, J = 
9.1 Hz, 1 H), 2.38 (s, 1 H), 1.34 (s, 3 H); HRESIMS calcd for C14H14Br2F3N2O3 m/z [M + H]+ 
476.9280, 474.9298, 472.9318, found 476.9276, 474.9302, 472.9326. 
Further elution of the original column above with 3-5% Et2O/CH2Cl2 gave the crude minor 
product (156), which was further purified by chromatography on silica gel, eluting with 0-
30% Et2O/petroleum ether (foreruns, including excess 154) and then with 0-3% Et2O/CH2Cl2, 
to give 156 (29%) as a cream solid: mp (CH2Cl2/pentane) 129-131 °C; 1H NMR (CDCl3) δ 
7.17 (br d, J = 9.1 Hz, 2 H), 7.05 (s, 1 H), 6.90 (br d, J = 9.2 Hz, 2 H), 4.33 (d, J = 15.0 Hz, 
1 H), 4.19 (d, J = 15.1 Hz, 1 H), 3.94 (d, J = 9.0 Hz, 1 H), 3.91 (d, J = 9.0 Hz, 1 H), 2.51 (s, 
1 H), 1.38 (s, 3 H); HRESIMS calcd for C14H14Br2F3N2O3 m/z [M + H]+ 476.9280, 474.9298, 
472.9318, found 476.9279, 474.9303, 472.9313. 
6-Bromo-2-methyl-2-{[4-(trifluoromethoxy)phenoxy]methyl}-2,3-dihydroimidazo[2,1-
b][1,3]oxazole (62). Reaction of alcohol 155 with NaH (1.25 equiv), using procedure C at 20 
°C for 20 min and then at 55 °C for 4 h, followed by chromatography of the product on silica 
gel, eluting with 33-50% CH2Cl2/petroleum ether (foreruns) and then with 50-75% 
CH2Cl2/petroleum ether, gave 62 (87%) as a cream solid (following trituration in cold 
pentane): mp 55-57 °C; 1H NMR (CDCl3) δ 7.14 (br d, J = 9.1 Hz, 2 H), 6.87 (br d, J = 9.2 
Hz, 2 H), 6.60 (s, 1 H), 4.30 (d, J = 9.5 Hz, 1 H), 4.16 (d, J = 9.8 Hz, 1 H), 4.04 (d, J = 9.8 
Hz, 1 H), 3.90 (d, J = 9.5 Hz, 1 H), 1.73 (s, 3 H); 13C NMR (CDCl3) δ 157.3 (C-7a), 156.6 
(C-1’), 143.8 (C-4’), 122.8 (2 C, C-3’,5’), 120.7 (q, JC-F = 256.5 Hz, 4’-OCF3), 115.8 (2 C, C-
2’,6’), 114.0 (C-6), 110.1 (C-5), 92.1 (C-2), 72.0 (2-CH2O), 52.1 (C-3), 23.5 (2-CH3). Anal. 
(C14H12BrF3N2O3) C, H, N. 
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2-Methyl-6-(methylsulfanyl)-2-{[4-(trifluoromethoxy)phenoxy]methyl}-2,3-
dihydroimidazo[2,1-b][1,3]oxazole (65). n-Butyllithium (0.58 mL of a 2.0 M solution in 
cyclohexane, 1.16 mmol) was added dropwise to a stirred solution of bromide 62 (303 mg, 
0.771 mmol) in anhydrous freshly distilled THF (7 mL) under N2 at -78 °C. After 80 min 
at -78 °C, methyl disulfide (0.28 mL, 3.16 mmol) was added dropwise, and the mixture was 
stirred at -78 °C for 3.5 h, slowly warmed to -20 °C (over 1 h), stored at -20 °C for 10 h, and 
finally stirred at 0 °C for 3 h. The reaction was then quenched with ice/aqueous citric acid (20 
mL), and the resulting mixture was added to water (30 mL), and extracted with CH2Cl2 (6 x 
50 mL). The combined extracts were evaporated to dryness under reduced pressure and the 
residue was chromatographed on silica gel. Elution with 0-1% Et2O/CH2Cl2 first gave 
foreruns, and then further elution with 5% Et2O/CH2Cl2 gave the crude product (0.12 g) as an 
8:1 mixture of isomers, which was crystallised from CH2Cl2/pentane, to give pure 65 (93 mg, 
33%) as a cream solid: mp 104-106 °C; 1H NMR (CDCl3) δ 7.15 (br d, J = 9.1 Hz, 2 H), 6.87 
(br d, J = 9.2 Hz, 2 H), 6.61 (s, 1 H), 4.26 (d, J = 9.5 Hz, 1 H), 4.15 (d, J = 9.6 Hz, 1 H), 
4.04 (d, J = 9.7 Hz, 1 H), 3.86 (d, J = 9.6 Hz, 1 H), 2.41 (s, 3 H), 1.73 (s, 3 H); 13C NMR 
(CDCl3) δ 158.7 (C-7a), 156.7 (C-1’), 143.7 (q, JC-F = 2.1 Hz, C-4’), 135.7 (C-6), 122.8 (2 C, 
C-3’,5’), 120.7 (q, JC-F = 256.4 Hz, 4’-OCF3), 115.8 (2 C, C-2’,6’), 111.9 (C-5), 91.6 (C-2), 
72.1 (2-CH2O), 51.8 (C-3), 23.5 (2-CH3), 18.7 (SCH3). Anal. (C15H15F3N2O3S) C, H, N. 
Minimum Inhibitory Concentration Assays (MABA and LORA). These were carried 
out according to the published protocols.50,51 
In Vitro Parasite Growth Inhibition Assays. The activity of test compounds against the 
amastigote stage of the L. don parasite was assessed at CDRI using a mouse macrophage-
based luciferase assay, carried out according to the reported procedures.25 Additional assays 
measuring the growth inhibitory action of compounds against L. inf, T. cruzi, and T. brucei
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and determining any cytotoxic effects on human lung fibroblasts (MRC-5 cells), were 
conducted at the University of Antwerp (LMPH), as described in a recent report.53 
Solubility Determinations. The solid compound sample was mixed with water or 0.1 M 
HCl (enough to make a 2 mM solution) in an Eppendorf tube, and the suspension was 
sonicated for 15 min and then centrifuged at 13000 rpm for 6 min. An aliquot of the clear 
supernatant was diluted 2-fold with water (or 0.1 M HCl), and then HPLC was conducted. 
The solubility was calculated by comparing the peak area obtained with that from a standard 
solution of the compound in DMSO (after allowing for varying dilution factors and injection 
volumes). 
Microsomal Stability Assays. Studies on compounds 7-9, 12, 18, and 47 (Table 3) were 
performed by Advinus Therapeutics Ltd., 21 & 22 Phase II, Peenya Industrial Area, 
Bangalore 560058, India, using a published protocol26 in which the compound concentration 
was 0.5 µM and the incubation time was 30 min. Additional analyses on compounds 5, 9, 27, 
37-39, 51, 54, 56, and 57 (Table 3) were carried out by WuXi AppTec (Shanghai) Co., Ltd, 
288 FuTe ZhongLu, WaiGaoQiao Free Trade Zone, Shanghai 200131, China. Here, test 
compounds (at 1 µM) were incubated at 37 °C with liver microsomes from human, CD-1 
mouse or hamster species in the presence of a NADPH regenerating system and phosphate 
buffer (100 mM, pH 7.4) at 0.5 mg/mL microsomal protein (the positive controls were 
testosterone, propafenone and diclofenac). Samples were removed at time intervals of 0, 5, 
10, 20, 30, and 60 mins and immediately mixed with cold CH3CN (containing 0.1 µg/mL of 
tolbutamide as an internal standard), then centrifuged prior to analysis by LCMS/MS. 
In Vivo Experiments. All animal experiments were performed according to institutional 
ethical guidelines for animal care. Antitubercular efficacy studies in mice were approved by 
the UIC IACUC (UIC AWA no. A3460-01; ACC application no. 12-183). For VL, mouse 
model studies (LSHTM) were conducted under license from the UK Home Office (license 
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no. PIL 70/6997), hamster studies at CDRI were approved by the CSIR-CDRI animal ethics 
committee (license no. 19/2009/PARA/IAEC), and hamster studies at LMPH were approved 
by the ethical committee of the University of Antwerp (UA-ECD 2010-17). 
Acute TB Infection Assay. Each compound (including 4, which was used as an internal 
reference standard) was administered orally to a group of 7 M. tb-infected BALB/c mice at 
100 mg/kg daily for 5 days a week for 3 weeks, beginning on day 11 postinfection, in 
accordance with published protocols.19,50 The results are recorded as the ratio of the average 
reduction in colony forming units (CFUs) in the compound-treated mice /the average CFU 
reduction in the mice treated with 4. In this assay, 4 caused 2.5-3 log reductions in CFUs. 
Acute VL Infection Assay (Mouse Model, LSHTM). Test compounds were orally dosed 
once per day for 5 consecutive days to groups of 5 female BALB/c mice infected with 2 x 107 
L. donovani amastigotes, with treatment commencing one week postinfection, as reported.25 
Miltefosine (3) and AmBisome were positive controls and parasite burdens were determined 
from impression smears of liver sections. Efficacy was expressed as the mean percentage 
reduction in parasite load for treated mice in comparison to untreated (vehicle-only) controls. 
Chronic VL Infection Assay 1 (Hamster Model, CDRI). Golden hamsters (weighing 40-
45 g) were infected intracardially with 1 x 107 L. donovani amastigotes and then, 15 days 
later, all animals were subjected to splenic biopsy to assess the level of infection. Groups of 
hamsters having an appropriate infection grading (5-15 amastigotes/100 spleen cell nuclei) 
were treated with test compounds, starting on day 17 and dosing orally once per day for 
either 5 or 10 consecutive days, according to the published procedure.25 Post-treatment 
splenic biopsies performed 12 days after the first dose were employed to determine the 
intensity of infection, as previously described.25 
Chronic VL Infection Assay 2 (Hamster Model, LMPH). Golden hamsters (weighing 
75-80 g) were infected with 2 x 107 L. infantum amastigotes and, 21 days post-infection, 
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treatment groups of 6 animals each were dosed orally once per day with test compounds 
(formulated in PEG400) for 5 consecutive days. Parasite burdens in three target organs (liver, 
spleen, and bone-marrow) were determined by microscopic evaluation of impression smears 
(stained with Giemsa) and efficacy was expessed as the mean percentage load reduction for 
treated hamsters in comparison to untreated (vehicle-only) controls. Miltefosine (3) was 
included as a reference drug in all experiments. 
Mouse Pharmacokinetics. The study was conducted by Advinus Therapeutics Ltd., 21 & 
22 Phase II, Peenya Industrial Area, Bangalore 560058, India, according to a published 
protocol.26 Briefly, compounds were administered to groups of male Swiss Albino mice (30-
40 g); intravenous dosing (at 1 mg/kg) employed a solution vehicle comprising 20% NMP 
and 40% PEG-400 in 100mM citrate buffer pH 3, while oral dosing (at 12.5 or 25 mg/kg) 
was as a suspension in 0.08% Tween 80/0.5% carboxymethylcellulose in water. Samples 
derived from blood plasma (at 0.083 for iv only, 0.25, 0.5, 1, 2, 4, 6, 8, 10, 24 and 48 h) were 
centrifuged prior to analysis by LC-MS/MS and the pharmacokinetic parameters were 
determined using WinNonlin software (Version 5.2). 
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ABBREVIATIONS USED 
NTD, neglected tropical disease; VL, visceral leishmaniasis; HAT, human African 
trypanosomiasis; L. don, Leishmania donovani; L. inf, Leishmania infantum; TB, 
tuberculosis; Ddn, deazaflavin-dependent nitroreductase; M. tb, Mycobacterium tuberculosis; 
DIPEA, N,N-diisopropylethylamine; vs., versus; T. cruzi, Trypanosoma cruzi; T. brucei, 
Trypanosoma brucei; HLM, human liver microsomes; MLM, mouse liver microsomes; 
HRCIMS, high resolution chemical ionization mass spectrometry; HRFABMS, high 
resolution fast atom bombardment mass spectrometry; HRESIMS, high resolution 
electrospray ionization mass spectrometry; APCI MS, atmospheric pressure chemical 
ionization mass spectrometry; MEK, methyl ethyl ketone (2-butanone); CFU, colony forming 
unit; SD, standard deviation. 
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Table 1. In vitro antiparasitic and antitubercular activities of nitroimidazooxazoles 
 
     IC50a,b (µM) MICc,b (µM) 
compd Fm X aza R L. don L. inf T. cruzi T. bruc MRC-5 MABA LORA 
10 A H  OCF3 0.03 0.11 0.60 >64 >64 14 43 
11 A Me  OCF3 0.08 0.28 0.42 60 60 0.24 34 
12 B H  OCF3 0.005 0.15 1.5 >64 >64 2.0 73 
13 Bd H  OCF3 0.02 0.33 4.7 >64 >64 0.32 70 
14 Be H  OCF3 0.05 0.50 2.6 >64 >64 3.1 >128 
15 C H  OCF3  48 9.8 33 31 >128 >128 
16 Cd H  OCF3  >64 >64 >64 >64 56 61 
17 Ce H  OCF3  >64 >64 >64 >64 >128 >128 
7f B Me  OCF3 0.03 0.33 1.8 >64 >64 0.077 55 
9g Bd Me  OCF3 0.03 0.17 2.6 53 >64 0.046 5.9 
18 Be Me  OCF3 0.03 0.77 1.6 38 >64 2.5 27 
19g B Me  H 0.14 0.30 1.8 >64 >64 0.16 22 
20 B Me  F 0.12 0.17 1.8 >64 >64 0.11 15 
21 B Me  Cl 0.12 0.20 2.4 57 >64 0.038 41 
22 B Me  CF3 0.28 0.41 2.5 >64 >64 0.058 46 
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23 B Me  OPh 0.25 2.2 4.5 8.9 >64 0.11 48 
24 D H  OCF3 0.06 0.32 7.1 50 >64 0.36 24 
25 D Me  OCF3 0.08 0.50 0.90 12 >64 0.40 9.7 
26f E     18 52 >64 >64 16 116 
27 B Me 2 CF3 0.21 0.24 1.7 >64 >64 0.038 28 
28 B Me 3 CF3 0.30 0.55 2.9 >64 >64 0.48 45 
29 B Me 2,3 CF3  1.4 2.2 >64 >64 0.91 106 
30 B Me 2,5 CF3  0.43 1.4 >64 >64 0.14 70 
31 B Me 2,6 CF3  0.50 1.5 >64 >64 0.47 >128 
32 F H  F 0.02 1.8 2.8 >64 >64 0.025 >128 
33 F H  CF3 0.11 3.8 2.8 >64 >64 0.040 >128 
34 F H  OCF3 0.01 0.83 1.4 3.1 >64 0.039 >128 
35 F H 2’ CF3  2.4 19 2.2 45 58 57 
36 F H 2’ OCF3 2.1 5.0 10 5.2 47 5.3 48 
37 F H 3’ F 0.07 0.03 1.3 >64 >64 0.049 42 
38 Fd H 3’ F  0.06 7.1 >64 >64 0.037 2.7 
39 Fe H 3’ F  0.03 0.95 >64 >64 0.46 3.8 
40 F H 3’ CF3 0.01 1.5 0.94 >64 >64 0.024 >128 
41 F H 3’ OCF3 0.01 0.76 1.4 4.2 >64 0.037 >128 
42 Gd H 3’ F  48 34 >64 54 >128 >128 
43 Ge H 3’ F  49 22 >64 55 84 >128 
8 F Me  F 0.06 3.3 0.52 9.2 >64 0.043 11 
44 Fd Me  F 0.06 2.3 2.8 >64 >64 0.046 4.0 
45 Fe Me  F 0.35 4.2 0.58 >64 >64 0.080 >128 
46 F Me  CF3 0.06 11 1.5 1.0 >64 0.081 >128 
47 F Me  OCF3 0.05 5.3 0.89 0.85 >64 0.088 64 
48 F Me 2’ F 0.20 2.9 0.65 >64 >64 0.024 35 
49 F Me 2’ CF3 0.11 3.6 0.85 16 >64 0.018 4.5 
50 F Me 2’ OCF3 0.07 26 2.4 8.9 >64 0.018 19 
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51 F Me 3’ F 0.04 0.13 0.99 >64 >64 0.036 35 
52 F Me 3’ CF3 0.06 5.2 2.5 >64 >64 0.023 >128 
53 F Me 3’ OCF3 0.03 11 1.6 3.9 >64 0.025 >128 
54 F Me 2’,2 F 0.15 0.14 1.2 40 >64 0.053 24 
55 F Me 2’,3 F 0.34 0.31 5.6 52 >64 0.091 14 
56 F Me 3’,3 F 0.09 0.57 7.9 >64 >64 0.37 39 
57 H    0.16 0.20 1.1 >64 >64 0.13 41 
58 I    0.63 0.23 1.1 12 >64 0.29 60 
59 J    0.81 1.7 3.6 >64 >64 0.23 29 
60f K     13 0.40 3.4 >64 0.051 26 
5g Kd     7.1 0.43 1.7 >64 0.033 2.3 
aIC50 values for inhibition of the growth of Leishmania donovani, Leishmania infantum, 
Trypanosoma cruzi, and Trypanosoma brucei, or for cytotoxicity toward human lung 
fibroblasts (MRC-5 cells). bEach value (except the single test L. don data) is the mean of at 
least two independent determinations. For complete results (mean ± SD) please refer to 
Supporting Information. cMinimum inhibitory concentration against M. tb, determined under 
aerobic (MABA)50 or hypoxic (LORA)51 conditions. dR enantiomer. eS enantiomer. fRef 30. 
gRef 18.  
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Table 2. In vitro antiparasitic and antitubercular activities of ring A analogues of 7 
 
   IC50a,b (µM) MICc,b (µM) 
compd Fm Y L. inf T. cruzi T. bruc MRC-5 MABA LORA  
7 A 6-NO2 0.33 1.8 >64 >64 0.077 55 
61 A 6-H >64 2.1 >64 >64 81 >128 
62 A 6-Br >64 22 33 34 55 51 
63 A 6-CHO >64 33 >64 >64 >128 >128 
64 A 6-CH2OH >64 >64 >64 >64 >128 >128 
65 A 6-SMe 57 9.4 >64 38 54 66 
66 A 6-SO2Me 57 >64 >64 >64 >128 >128 
67 A 5-Br 30 0.13 33 26 61 61 
68 A 5-SMe >64 0.58 33 25 27 70 
69 A 5-SO2Me >64 20 >64 >64 >128 >128 
70 B NO2 >64 0.59 20 >64 >128 >128 
71 B Br >64 13 60 43 46 >128 
72 C NO2 >64 4.7 34 >64 52 >128 
aIC50 values for inhibition of the growth of Leishmania infantum, Trypanosoma cruzi, and 
Trypanosoma brucei, or for cytotoxicity toward human lung fibroblasts (MRC-5 cells). bEach 
value is the mean of at least two independent determinations. For complete results (mean ± 
SD) please refer to Supporting Information. cMinimum inhibitory concentration against M. tb, 
determined under aerobic (MABA)50 or hypoxic (LORA)51 conditions. 
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Table 3. Aqueous solubility, microsomal stability, and in vivo antileishmanial efficacy data 
for selected analogues 
 
 aq solubilitya 
(µg/mL) 
microsomal stabilityb 
[% remaining at 1 (0.5) h] 
in vivo efficacy against L. don (mouse) 
(% inhibition at dose in mg/kg)c 
compd pH=7 pH=1 H M Ham 25 12.5 6.25 3.13 1.56 0.78 0.39 
12 0.91  (99) (76) (54) >99  89     
13 0.96       74     
14 1.2       76     
7 3.6  (86) (79) (49) 100 >99 99 64 31 7  
9 2.4  (92) (89) 18 (54)  >99 >99 83 49 11  
18 2.6  (84) (70) (64)  84 19 8    
24 23 11d           
27 11 11d 84 69  >99  83     
28 50            
30 27            
31 4.2            
32 0.059            
37 1.3 526 60 47  >99  100 >99 98   
38 1.1 260 57 54      52 45 36 
39 1.4 299 61 41      59 46 13 
8 0.23  (88) (57) (42) >99 93 68     
44 0.075       36     
45 0.068       6     
47 0.021  (91) (100) (79) 42       
48 0.19 2.7           
51 1.1 634 58 21  >99  100 93 34   
54 3.1 46 71 52  >99  96 94 47   
 62 
55 3.3 19           
56 10  82 62  91       
57 14 19100 49 14  >99  16     
58 2.6 23200           
5 0.31 116   55        
aSolubility (µg/mL) in water (pH = 7) or 0.1 M HCl (pH = 1) at 20 °C, determined by 
HPLC (see Experimental Section). bPooled human (H), CD-1 mouse (M), or hamster (Ham) 
liver microsomes; data in brackets are the percentage parent compound remaining following a 
30 min incubation. cDosing was orally, once daily for 5 consecutive days; data are the mean 
percentage reduction of parasite burden in the liver. dUnstable under assay conditions. 
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Table 4. Pharmacokinetic parameters for selected compounds in male Swiss Albino mice 
 
 
 
compd 
intravenous (1 mg/kg)  oral (12.5 or 25 mg/kg)a 
C0  
(µg/mL) 
CL 
(mL/kg/
min) 
Vdss  
(L/kg) 
t1/2  
(h) 
AUClast 
(µg⋅h/mL) 
 
Cmax 
 (µg/mL) 
Tmax 
 (h) 
AUClast 
(µg⋅h/mL) 
Fb 
(%) 
12 0.61 13 2.2 3.2 1.14  1.8 1.0 14.8 52 
7 0.88 9.5 1.7 2.2 1.69  4.1 4.0 33.5 79 
9 0.36 11 2.6 2.7 1.39  1.3 2.0 15.8 91 
8 0.30 28 7.5 3.8 0.48  0.70 6.0 7.58 63 
47 0.34 7.6 5.7 11 2.13  0.29 6.0 9.81 18 
aThe oral dose for 9 was 12.5 mg/kg; the remainder were dosed at 25 mg/kg. bOral 
bioavailability, determined using dose normalised AUClast values. 
  
 64 
Table 5. In vivo efficacy of 5 and 9 against L. infantum in the early curative hamster model 
(LMPH) 
 
 
compd 
dosage a 
(mg/kg) 
% inhibition in target organs 
liver spleen bone marrow 
3 20 81.8 92.0 84.7 
5 50 65.7 51.3 21.7 
 25 53.9 42.9 37.3 
 12.5 32.5 24.8 23.7 
9 50 100 100 100 
 25 100 99.9 99.7 
 12.5 99.0 98.7 94.0 
aAll compounds were dosed orally once daily for 5 consecutive days.  
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Figure 1. Structures of various antileishmanial or antitubercular agents 
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Figure 2. Comparative in vivo efficacy in the mouse VL model: a) 6.25 mg/kg; b) 1.56 
mg/kg 
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Figure 3. Comparison of 4, 9, 18, and 44 with rifampicin in the acute TB infection mouse 
model 
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Scheme 1a 
 
a Reagents and conditions: (i) 4-OCF3BnBr, NaH, DMF, 0-20 °C, 7-21 h; (ii) DIPEA, 105-
108 °C, 6.5-15 h; (iii) NaH, DMF, 0 °C, 0.7-1.4 h or 0-20 °C, 2-3 h; (iv) m-CPBA, Na2HPO4, 
CH2Cl2, 0-20 °C, 3-3.5 h; (v) 4-OCF3PhOH, K2CO3, acetone, 59 °C, 36-41 h; (vi) 4-
OCF3PhOH, CsF, DMF, 20 °C, 35-45 h; (vii) DIPEA, toluene, 79-80 °C, 24 h.  
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Scheme 2a 
 
a Reagents and conditions: (i) ArOH, NaH, DMF, 0-55 °C, 2-3 h, or 0-80 °C, 5-30 min; (ii) 4-
OCF3PhNH2 or 4-OCF3PhNHMe, CoCl2, CH3CN, 63-65 °C, 24-52 h; (iii) NaH, DMF, 0-20 
°C, 1.3-2.8 h (or 0 °C, 2 h); (iv) K2CO3, DMF, 65 °C, 33 h; (v) OsO4, NMO, CH2Cl2, 20 °C, 8 
h; (vi) TIPSCl, imidazole, DMF, 20 °C, 6.5 d; (vii) 40% HF, CH3CN, 20 °C, 11 h; (viii) ArX 
(105, 106, 107, or 108), NaH, DMF, 0-20 °C, 1-2.5 h.  
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Scheme 3a 
 
a Reagents and conditions: (i) 4-IPhOH, K2CO3, acetone, 59 °C, 52 h; (ii) DIPEA, 100-105 
°C, 6-13 h; (iii) NaH, DMF, 0-20 °C, 1.7-4 h; (iv) ArB(OH)2, (DMF), toluene, EtOH, 2 M 
Na2CO3, Pd(dppf)Cl2 under N2, 85-90 °C, 0.8-4.5 h; (v) 1% HCl in 95% EtOH, 20 °C, 6.5 h; 
(vi) ArF (118, 120, or 121), NaH, DMF, 0-20 °C, 2.5-3.7 h; (vii) EtOCH2Cl, K2CO3, DMF, 0-
20 °C, 24 h; (viii) 1.25 M HCl in MeOH, 54-55 °C, 5 h; (ix) ArOH (125, 129, or 133), 
K2CO3, MEK, 65 °C, 39-49 h; (x) 125, NaH, DMF, 20 °C, 40 h; (xi) DIPEA, toluene, 80 °C, 
24 h.  
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Scheme 4a 
 
a Reagents and conditions: (i) 4-IPhOH, K2CO3, NaI, DMF, 72 °C, 24 h; (ii) DIPEA, 108 °C, 
14.5 h; (iii) NaH, DMF, 0 °C, 1-1.5 h; (iv) ArB(OH)2, (DMF), toluene, EtOH, 2 M Na2CO3 
(or 2 M KHCO3), Pd(dppf)Cl2 under N2, 78-92 °C, 0.75-3 h; (v) NaH, DMF, 0-20 °C, 2.5 h; 
(vi) 145, Cs2CO3, CuCl, dppf, DMF, Pd(dppf)Cl2 under N2, 85 °C, 4.3 h; (vii) 6-Br-pyridin-3-
ol, NaH, DMF, 0-50 °C, 4 h; (viii) MEK, (CHCl3), 65-80 °C, 18-72 h; (ix) triphosgene, Et3N, 
THF, 0-20 °C, 1.7 h, then 148, THF, 20 °C, 3.5 h. 
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Scheme 5a 
 
a Reagents and conditions: (i) DIPEA, (toluene), 104-109 °C, 12-16 h; (ii) NaH, DMF, 0-20 
°C, 80 min (for 61), or 55 °C, 4 h (for 62), or 45 °C, 2.5 h (for 67); (iii) nBuLi, THF, -78 °C, 
80 min, then DMF or (MeS)2, -78 to 20 °C, 4 h (for 63), or -78 to 0 °C, 18 h (for 65), then aq 
citric acid; (iv) NaBH4, EtOH, 0 °C, 1 h; (v) m-CPBA, Na2HPO4, CH2Cl2, 0-20 °C, 18-26 h; 
(vi) MeSH, Et3N, MeOH, 0-10 °C, 3 h. 
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